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I had always intended on attending Veterinary School, but when my mother was 
diagnosed with an aggressive form of Breast Cancer in 2008 my eyes were opened to a career 
path I had not considered. In August of 2015, I enrolled in the Biochemistry Graduate Program at 
the University of New Hampshire with the personal goal of participating in cancer research. 
When I arrived on campus I began exploring the various research opportunities. At this time, I 
became familiar with the work of Research Professor, Dr. Vernon Reinhold who introduced me 
to the field of Glycomics. My previous experience with glycomics had been a single brief lecture 
in my undergraduate Biochemistry course. I was immediately intrigued by the vast and critical 
influence glycosylation could have on cell function and human health and surprised by the lack 
of attention these post-translational modifications received.  
When I began my second rotation in the laboratory of Reproductive Physiologist, Dr. 
David Townson, I was presented with previous Masters Student, Brian Sullivan’s, research 
project investigating the functional role of cytokeratin intermediate filaments 8/18 (K8/18), 
which had been previously noted to be up-regulated in more aggressive cervical cancers. 
Through Brian’s work, the Townson group discovered that within the cervical cancer cell line, 
HeLa cells, two cellular phenotypes could be identified; those expressing K8/18 and those 
lacking K8/18 expression. The two phenotypes were separated by serial dilution in order to 
analyze various parameters of cell survival and immune system evasion. The study supported the 
hypothesis that reduced K8/18 expression increased cellular susceptibility to immune mediated 
death, specifically by the cytokines Fas Ligand (FasL) and Tumor Necrosis Factor α (TNF-α). 
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This work suggested that K8/18 filaments provided protection against immune mediated death, 
subsequently allowing for the progression of neoplastic disease.  
This work led me to ask the question, what is the mechanism that provides this 
protection? Having just completed my rotation in the UNH Glycomics Center, I went to the 
literature to determine if, and how, K8/18 filaments are glycosylated. I soon discovered Keratin 
18 filaments are highly phosphorylated and glycosylated. However, this protein is not 
glycosylated in the traditional branched chain formation but is O-linked β-N-
acetylglucosaminylated (O-GlcNAcylated). This discovery led me down a winding and 
fascinating path into a relatively new and exciting area of science. I initially used Brian’s work 
as a jumping off point and began investigating the role of O-GlcNAcylation in cervical cancer 
disease progression and metastasis. This led to my first publication, “O-GlcNAcylation enhances 
the tumorigenic properties of cervical cancer cells in vitro.(Jaskiewicz, Hermawan, Parisi, & 
Townson, 2017)” (Chapters 2 and 3). 
Shortly after completing this work I was presented with the opportunity to move to the 
University of Vermont (UVM) with Dr. Townson and the laboratory. I eagerly accepted the offer 
and prepared to move. When we arrived at UVM, I spent several months working with Dr. 
Townson to establish the new laboratory and explore new opportunities at the University. 
Perhaps one of the most exciting components of this transition was the close proximity of the 
main campus to the University of Vermont College of Medicine. This opened up a number of 
resources that have furthered my research and training.  
xi 
 
It was at this time that I contacted Dr. Elizabeth McGee, an OB/GYN research physician, 
for guidance with continuing my research. After consulting with Dr. McGee, it was decided that 
while the results of my first study were interesting and warranted further investigation, the 
clinical relevance of studying O-GlcNAcylation in cervical cancer was not clear. However, O-
GlcNAcylation’s connection to diabetes encouraged us to transition to an endometrial cancer cell 
model. Women with Type II Diabetes have a 2-3 fold increased risk of developing endometrial 
cancer, and mRNA analysis of endometrial tumors showed an increase in the O-GlcNAc cycling 
enzyme mRNA in the leading edge of tumors. This led to my second manuscript, “Hyper-O-
GlcNAcylation promotes Epithelial-Mesenchymal Transition in endometrial cancer cells,” which 
is currently in revision for the journal, Oncotarget. (Chapter 4). Finally, my interest extended 
from disease progression to possible treatment interference, and in my final manuscript I focused 
on the impact hyper-O-GlcNAcylation may have on the efficacy of progesterone treatment to 
reduce invasion and cell proliferation in endometrial cancer (Chapter 5).  
Throughout my graduate student career, I was incredibly fortunate to be afforded the 
independence to build a research project that both supported my interest in women’s health and 
facilitated an interdisciplinary research education. I hope that you will recognize the unique 
graduate experience that Dr. Townson supported and guided me through in the proceeding 
chapters. As my graduate student career draws to an end, I look forward to continuing to explore 
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Hyper-O-GlcNAcylation of proteins is a subsequent artifact of metabolic disorder and is 
indicative of many cancers, including cancers of the female reproductive tract. While the 
incidence of most cancer types has been declining in the U.S., endometrial and cervical cancer 
remain among the most common cancers diagnosed in women. Diabetic women have a 2-3 fold 
increased risk of developing endometrial cancer, and tend to have more aggressive cases of 
cervical cancer, however, the molecular aspects of these risks are not fully understood. This 
study investigated the alteration of cellular O-GlcNAcylation of proteins as the potential 
mechanistic connection between diabetes and tumorigenicity in cancers of the female 
reproductive tract. The cervical cancer cell line (SiHa) and the endometrial cancer cell line 
(Ishikawa) were utilized to study the effect of dysregulation of O-GlcNAcylation on the 
proliferation, migration, invasion, and related molecular mechanisms. In cervical cancer, O-
GlcNAcylation was found to be an important regulator of tumorigenicity. Overall, inhibition of 
O-GlcNAcylation (via the inhibitor, OSMI-1) in SiHa cells impaired cell proliferation (p<0.01) 
and invasion (p<0.01) yet did not affect cell cycle progression. These effects occurred 
xiii 
 
concomitantly with an alteration of cellular morphology, principally the disruption/decline of 
K8/18 and β-actin filament expression.  The results suggest O-GlcNAcylation regulates several 
aspects of tumorigenesis in cervical cancer cells, and cytoskeletal proteins are among the targets. 
Similarly, in endometrial cancer cells, hyper-O-GlcNAcylation (via 1μM Thiamet-G/ThmG or 
25mM Glucose) enhanced the expression of EMT-associated genes (WNT5B and FOXC2), and 
the E-Cadherin suppressor, Snail. Reorganization of actin filaments into stress filaments, 
consistent with EMT, was also noted in ThmG-treated cells. Interestingly, Hypo-O-
GlcNAcylation (via 50 μM OSMI-1) also upregulated WNT5B, inferring that any disruption to 
O-GlcNAc cycling impacts EMT. However, Hypo-O-GlcNAcylation reduced cellular 
proliferation/migration and the expression of the pro-EMT genes (AHNAK, TGFB2, FGFBP1, 
CALD1, TFPI2). Finally, Ishikawa cells were used to investigate the effect hyper-O-
GlcNAcylation on the efficacy of progesterone (P4) in therapy for endometrial cancer 
proliferation and invasion. Ishikawa cells were exposed to ThmG, to induce hyper-O-
GlcNAcylation, and 100nM P4. P4 alone, significantly decreased cell proliferation, however, the 
addition of ThmG, and subsequent hyper-O-GlcNAcylation, negated this affect, returning the 
cells to control level proliferation (p<0.05). A similar pattern was noted in Matrigel invasion 
assays, where Hyper-O-GlcNAcylation augmented invasion compared to P4 treatment alone, 
both with and without progesterone treatment (p<0.05). Progesterone treatment has been shown 
to induce the expression of p21 and p27, reducing cell growth. In this study, P4 maintained p21 
expression and increased p27 expression, however, ThmG decreased p27 expression and the 
expression of endogenous progesterone receptor B (PR B) despite P4 treatment. These results 
suggest that hyper-O-GlcNAcylation, common in obese and diabetic patients, may promote 
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tumorigenicity in female cancers and could impair the efficacy of progesterone treatment. O-
GlcNAcylation has the potential to serve as a biomarker for early diagnosis and could predict 
treatment success. O-GlcNAc cycling enzyme inhibitors could prove to be useful tools for 



































LITERATURE REVIEW AND RESEARCH PROPOSAL 
 
Glycobiology 
There are four major classes of macromolecules that come together to support all living 
organisms; nucleic acids, protein, lipids, and carbohydrates. While nucleic acids (transcription) 
and proteins (translation) have been the focus of substantial biological research, referred to as the 
Central Dogma of Biology, carbohydrates have long been down played as a mere means for 
energy storage. Despite the discovery of protein bound glycans in the 19th Century, the 
importance of glyco-proteins and glyco-lipids has only recently been realized by the scientific 
community (Schachter, 2001).  While carbohydrates do serve the purpose of energy storage in 
the form of glucose and glycogen, protein glycosylation is considered one of the major forms of 
protein post-translational modification, massively contributing to the vast diversity of the 
proteome (Love et al., 2010).  
Glycans, which are branched chain polysaccharides, can be bound to proteins by 
asparagine-linkage (N-linked) or serine/threonine linkage (O-linked). These branched chains are 
comprised of 6 different sugar moieties: mannose, GlcNAc, Neu5Gc, Galactose, Sialic Acid, and 
Fucose.  N-linked and O-linked glycosylation are major structural components of both cell 
surface and secreted proteins, and significantly influence their structure and function (Varki et 
al., 2009). The biological significance of these structures is highlighted by debilitating glycan 
associated diseases (Freeze & Schachter, 2009; Varki et al., 2009). A complete lack of N-
glycosylation is fatal, but several genetic defects resulting in partial N-glycan pathway 
dysfunction result in extensive disability including severe mental retardation, epilepsy, and 
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failure to thrive (Hudson H. Freeze, n.d.). In recent years, it has become clear that several forms 
of Muscular Dystrophy stem from under-glycosylation by O-mannose (Kanagawa & Toda, 
2006). While our biological understanding of glycosylation has flourished in the past decades, 
there is still much to be learned about a unique form of O-linked glycosylation, β-N-
acetylglucosamine (O-GlcNAc). 
The history and biochemistry of O-GlcNAcylation 
O-GlcNAcylation was first described by Hart, et al. in 1984. Originally investigating the 
presence of surface glycans with terminal GlcNAc residues, Hart et al. discovered evidence 
suggesting the “-presence of O-glycosidicly linked monosaccharides on many lymphocyte cell 
surface proteins (Torres & Hart, 1984). Additionally, they discovered a majority of these 
moieties appeared to be intracellular, thus a novel single moiety form of glycosylation was 
discovered. In the 34 years since this ground breaking publication, more than 1,400 peer 
reviewed papers discussing O-GlcNAc have been produced (Lefebvre & Issad, 2015), and while 
many of its important mechanisms have been determined, O-GlcNAcylation and its relationship 
to disease is still largely an enigma.  
While we know substantially less about O-GlcNAcylation compared to some of its 
branched counterparts, it is surprising to note that O-GlcNAcylation is both ubiquitous and 
abundant in eukaryotic cells. To date, more than 600 O-GlcNAcylated proteins have been 
identified, and more are discovered each day. O-GlcNAcylation is a unique form of 
glycosylation in many ways. While glycosylation is generally an extra-cellular protein 
modification, O-GlcNAcylation occurs in nearly all intracellular compartments. It is found 
mostly within the nuclear and cytoplasmic compartments. Beyond its general abundance, O-
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GlcNAcylation is remarkable for its highly dynamic nature, akin to phosphorylation as a post-
translational modification (Wells et al., 2002). In contrast to phosphorylation, O-GlcNAc 
modification is regulated by just two highly-conserved enzymes.  β-N-acetylglucosamine 
transferase (O-GlcNAc Transferase, OGT) is one of these enzymes and is responsible for adding 
the free form substrate UDP-O-GlcNAc to serine and threonine residues on proteins by beta-
glycosidic linkage. Conversely, β-N-acetylglucosaminase (O-GlcNAcase, OGA) removes the 
modification from proteins (F. V Rao et al., 2006).  
O-GlcNAc Transferase is heterotrimeric, consisting of two 110 kDa and one 78 kDa sub-
units, encoded by the OGT gene, which is located on the X chromosome (Xq13). As mentioned 
previously, OGT is highly conserved from worms to humans, and complete inhibition of the 
enzyme is lethal (Shafi et al., n.d.). Three isoforms of the enzyme have been identified: a full 
length (ncOGT), a short length (sOGT), and a mitochondrial variant (mOGT). OGT is tyrosine 
phosphorylated, and is O-GlcNAcylated itself, possibly operating as its own regulator of 
expression (Aquino-Gil, Pierce, Perez-Cervera, Zenteno, & Lefebvre, n.d.). Comparatively, 
OGA is a hydrolase enzyme encoded for by the Meningioma Expressed Antigen 5 (MGEA5) 
gene, located on chromosome 10 (10q24.32) (Comtesse, Maldener, & Meese, 2001). There are 3 
known isoforms of OGA;  a full length (fOGA), a short length (sOGA), and a variant of OGA 
(vOGA) (Alonso, Schimpl, & van Aalten, 2014). 
Current tools and techniques for studying O-GlcNAcylation 
O-GlcNAcylation is described by glycobiologist, John Hanover, as the dark matter of the 
glycobiology field (Bond & Hanover, 2015). For nearly 60 years, O-GlcNAcylation has 
influenced cellular functions without first being identified. This modification evaded scientific 
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discovery for so long because of its small size and labile nature (Greis & Hart, 1998). For 
instance, cells have abundant, intrinsic hydrolases, which can remove O-GlcNAc during protein 
purification. Further, unlike charged post-translational modifications or PTMs, such as 
phosphorylation, O-GlcNAcylation has no charge and thus does not influence the migration 
pattern of a protein during gel electrophoresis. Additionally, the addition of an O-GlcNAc 
molecule (+203), typically does not impact the apparent molecular mass of a protein, unless there 
are many clustered O-GlcNAc modifications. These characteristics also make detection by mass-
spectrometry difficult, as O-GlcNAc modifications tend to be lost during ionization; the free O-
GlcNAc is then overshadowed by abundant peptides (Varki et al., 2009; Zhongping Tan and Lai-
Xi Wang, 2017; Trinidad, et al., 2012).  
While O-GlcNAcylation presents many structural and analytical challenges, several 
techniques have been developed to overcome these.  For example, the development of a 
monoclonal antibody for O-GlcNAc modified proteins (CTD 110.6) facilitated the efficient 
detection and purification of O-GlcNAcylated proteins (Whelan & Hart, 2006). There are also 
several tools for the manipulation of O-GlcNAcylation, such as small molecule inhibitors of 
OGA and OGT, cell culture supplementation of glutamine and glucose, small interfering 
(siRNA) or short hairpin RNA (shRNA), and now CRISPR/Cas9 (Banerjee, Hart, & Cho, 2013; 
Esko & Bertozzi, 2009; E. J. Kim, Bond, Love, & Hanover, 2014).  
Pharmacological inhibitors of OGA exist, N-Acetylglucosaminono-1,5-lactone O-
(phenylcarbamoyl)oxime (PUGNAc) (Horsch, Hoesch, Vasella, & Rast, 1991), and Thiamet-G 
(Yuzwa et al., 2012) are those most notable. The OGA inhibitors PUGNAc  has been widely 
used to induce a state of hyper-O-GlcNAcylation in a variety of cell types and cell culture 
systems (Ali Mehdy, Willy Morelle, Claire Rosnoblet, Dominique Legrand, Tony Lefebvre, 
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2011; Seung Yoon Park, Ryu, & Lee, 2005; Vosseller, Wells, Lane, & Hart, 2002). While both 
OGA inhibitors are effective, Thiamet-G has been identified as the more specific inhibitor as it 
has higher Ki value for OGA than PUGNAc, and is a more stable bioactive inhibitor of OGA 
(Banerjee et al., 2013; Yuzwa et al., 2008). 
On the other hand, the development of reliable OGT inhibitors has been extremely 
difficult.  For instance the drug Alloxan, often used to induce diabetes in mice (Moley, Pellicer, 
& Decherney, n.d.), also has OGT inhibitory effects (Konrad et al., 2002). However, Alloxan 
was known to be cytotoxic and has many off target effects beyond the inhibition of OGT, such as 
the “formation of the reactive oxygen species (ROS) superoxide anions (O2−), hydroxyl radical 
(OH·) and hydrogen peroxide (H2O2), causing cell damage through a number of complex 
interactions probably involving several different cellular structures” (Zhang, Gao, & Brunk, 
1992), and for this reason is not considered a suitable OGT inhibitor. After this, Ac4-5S-GlcNAc 
and BADGP, mimics of the OGT donor substrate UDP-GlcNAc were used, however they caused 
indirect inhibition of other glycotransferases, impacting cell surface glycan expression (Liu et al., 
2017).  In the interim, the chemotherapeutic drug, 6-Diazo-5-oxo-L-norleucine (DON) (Henry 
W. Dion, Salvatore A. Fusari, Zbigniew L. Jakubowski & Bartz, 1956) has some indirect 
potential.  This drug suppresses the presence of UDP-GlcNAc by inhibiting the enzyme 
glutamine: fructose-6-phosphate-amido- transferase-1 (GFAT-1).  The inhibition of GFAT-1, in 
turn, limits the catalytic ability of the Hexosamine Biosynthesis Pathway (HBP), of which the 
end product is the OGT substrate, UDP-GlcNAc (Marshall, Bacote, & Traxinger, 1991). More 
recently, the Walker laboratory at Harvard developed a small molecule inhibitor of OGT, OSMI-
1, which effectively inhibits O-GlcNAcylation without impacting transmembrane protein 
glycosylation (Ortiz-Meoz et al., 2015). Around this same time, similar inhibitors were also 
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introduced to the market in the form of various small molecule and bi-substrate inhibitors (E. J. 
Kim et al., 2014; Trapannone, Rafie, & Van Aalten, 2016).   
While pharmacological manipulation is an important tool for preliminary research, these 
small molecule inhibitors can have unintended consequences. Thus, molecular tools have 
become critical for advancing our knowledge.  This includes the use of small interfering RNAs 
(siRNAs) and short hairpin RNAs (shRNA) to disrupt transcriptional/translational events (D. D. 
Rao, Vorhies, Senzer, & Nemunaitis, 2009), or for specific site knockout, point mutations 
(Butkinaree et al., 2008). Several studies have been published utilizing point mutation 
technology to eliminate an O-GlcNAc binding site of interest. In this technique, minor point 
mutations are made at the DNA or RNA level to result in the substitution of a neutral amino acid 
residue (typically alanine (Ala)) for a serine or threonine glycosylation site. In example, when O-
GlcNAcylated serine 30, 31, and 49 of K8/18 filaments are replaced by alanine residues in 
transgenic mice, the non-glycosylated mutant mice are more susceptible to liver and pancreatic 
injury/apoptosis compared to wild-type mice. The loss of O-GlcNAc resulted in inactivation and 
reduced phosphorylation of Akt1 and Protein Kinase Cθ, suggesting that O-GlcNAcylation 
supports the phosphorylation of cell-survival kinases (N.-O. Ku, Toivola, Strnad, & Omary, 
2010).  
Cellular effects of O-GlcNAcylation 
Because O-GlcNAc and O-phosphate both modify threonine and serine residues, they 
frequently compete with each other for binding. In fact, in many instances, O-GlcNAcylation 
inhibits phosphorylation (Hart, Slawson, Ramirez-Correa, & Lagerlof, 2011). One mechanism to 
explain this phenomenon is the observation that OGT forms complexes with some phosphatases 
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(Chen et al., 2008; Wells, Kreppel, Comer, Wadzinski, & Hart, 2004), which presumably 
activates them and then cleaves phosphates from the targeted proteins. Inhibition can also be 
attained through direct competition of shared binding sites or steric hindrance in adjacent 
residues (Z. Wang et al., 2010). Additionally, instances have been noted where the presence of 
an O-GlcNAc moiety on one residue of a protein can impair phosphorylation at a distant site 
(Comer & Hart, 2000). One example of this is the cytoskeletal intermediate filament component 
keratin 18 (Tao et al., 2006), however the mechanism of inhibition is still unclear. 
 O-GlcNAcylation has a diverse set of cellular functions in that it can control protein 
stability (Sang Yoon Park et al., 2010; Srikanth, Vaidya, & Kalraiya, 2010a; Yuzwa et al., 2012), 
influence enzymatic activity, and affect protein-protein interactions, including 
transcription/translation (Hardivillé & Hart, 2014; Tarik Issad & Kuo, 2008), cell structure 
(Rotty, Hart, & Coulombe, 2010), cell cycle regulation (Jiang et al., 2016; Phie Tan, Duncan, & 
Slawson, n.d.) and perhaps most notably, metabolism (Jóźwiak, Forma, Bryś, & Krześlak, 
2014a). The novelty of O-GlcNAcylation as a sentinel to cellular metabolism is the origin of its 
nucleotide sugar substrate, UDP-GlcNAc. UDP-GlcNAc is the end-product of the Hexosamine 
Biosynthesis Pathway (HBP).  Approximately 2-5% of all glucose that enters the cell is shuttled 
into the HBP by the addition of glutamine to Frustose-6-Phosphate. Further, the fatty acid, 
Acetyl-CoA and the nucleotide, Uridine Tri-Phosphate (UTP) pathways converge to be 
incorporated into UDP-GlcNAc (Frank, 2012). Thus, the direct link of the HBP to glycolysis and 
the amino acid, fatty acid, and nucleotide metabolic pathways make O-GlcNAcylation the ideal 
nutrient-sensing modification. As such, the occurrence of hyper-O-GlcNAcylation is associated 
with the development of insulin resistance (IR) (Vosseller et al., 2002) and is a characteristic of 
Type 2 Diabetes (T2D) and many of its comorbidities (J. Ma & Hart, 2013). Today, many 
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scientists consider the development of IR as an adaptive mechanism to protect cells when 
nutrients, such as glucose and lipids, are too abundant.  
In light of the above observations, it is hypothesized that a high prevalence of O-
GlcNAcylation in cells provides the trigger for an IR response.  Indeed, experimental 
overexpression of OGT, which in turn leads to hyper-O-GlcNAcylation, triggers IR in mice 
(Yang et al., 2008). Moreover, many of the effects of O-GlcNAc on intracellular signaling are 
attributed to the large number of transcription factors that are O-GlcNAcylated, which ultimately 
influence gene expression (Tarik Issad & Kuo, 2008). 
 Diabetes mellitus (DM) is a group of metabolic diseases characterized by 
hyperglycemia. Type 1 Diabetes (T1D) stems from the failure of the pancreas to produce 
sufficient insulin, the peptide hormone that promotes the absorption of glucose in the cell. Type 
2 Diabetes (T2D) is the failure of cells to respond properly to the insulin that is being produced, 
known as insulin resistance (IR), which in addition to hyperglycemia can cause 
hyperinsulinemia. Although the mechanisms which lead to development of T1D remain unclear, 
several risk factors linked to the onset of T2D have been identified. These include the modifiable 
risk factors of overweight, unhealthy diet, and physical inactivity. These same risk factors also 
lead to an increased flux of glucose into the HBP, prompting the global hyper-O-GlcNAcylation 
of proteins (C. Slawson, Copeland, & Hart, 2010). For instance, a recent study showed that 
consumption of a Western diet (high in saturated fats and carbohydrates) led to increased O-
GlcNAcylation in rats (Medford, Chatham, & Marsh, 2012). Increases in O-GlcNAcylation 
(hyper-O-GlcNAcylation) are directly linked to insulin resistance and hyperglycemia-induced 
glucose toxicity (McClain, 2002). Moreover, there are several proposed mechanisms for the link 
between T2D and O-GlcNAcylation. The current working model proposes O-GlcNAc to be a 
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nutrient sensing “master switch” that attenuates cellular responses to extracellular stimuli, such 
as the metabolic state. In this case, excess glucose within the cell results in an accumulation of 
fructose-6-phosphate, which then is shunted to the HBP, causing increased O-GlcNAcylation. 
The effect establishes a negative feedback loop through the rate limiting enzyme GFAT, which 
then reduces the rate of glucose transport in response to insulin stimulation (Ruan, Singh, Li, 
Wu, & Yang, 2013). 
O-GlcNAcylation and Cancer 
Obesity, diabetes, and excess nutrient intake increase one’s risk for developing several 
types of cancer (Calle & Kaaks, 2004; Zelenko & Gallagher, 2014). For example, metabolic 
disorders are linked to an increased risk of cancers of the digestive and women’s reproductive 
tracts including pancreas (F. Wang, Herrington, Larsson, & Permert, 2003), liver (Adami et al., 
1996), breast (Larsson, Mantzoros, & Wolk, 2007), colorectal (Meyerhardt et al., 2003), urinary 
tract (Xu, Huo, Chen, & Yu, 2017), and female reproductive organs (Byrne et al., 2014; Cantrell 
et al., 2010; Shoff & Newcomb, 1998). As such, hyper-O-GlcNAcylation is a frequent harbinger 
of these cancers (Z. Ma & Vosseller, 2013). The two most critical nutrients to cell proliferation 
and growth in cancer are glucose and glutamine, a phenomenon often described as the Warburg 
effect (Tekade & Sun, 2017). In the 1960’s Otto Warburg discovered that cancer cells, in 
comparison to their normal counterparts, more heavily depended upon anaerobic metabolism, 
rather tradition aerobic metabolism, for proliferation and growth even when oxygen is present. In 
the average cell, glucose is metabolized to pyruvate, and then enters the Kreb Cycle in the 
mitochondria, where the majority of the energy for the cell is generated through oxidative 
metabolism. In cancer cells, conversely, glucose is still metabolized to pyruvate, but instead of 
undergoing oxidative metabolism, it is converted to lactic acid and secreted by the cell. This less 
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efficient form of metabolism is nevertheless viewed as a resourceful mechanism to enable the 
rapidly proliferating cancer cells to meet ongoing demands for anabolism of macromolecules 
(Heiden et al., 2009). In this context, the shift in metabolism of cancer cells has become a focal 
point for the development of new chemotherapeutic drugs.  
 The nutrient sensing characteristics of OGT link the HBP to oncogenic signaling and 
subsequent regulation of glucose and lipid metabolism. Additionally, metabolic reprogramming 
in cancer cells is connected to epigenetic changes, including effects of O-GlcNAcylation on 
histone modification and regulation of transcription factors (Singh, Zhang, Wu, & Yang, 2015). 
For example, Hypoxia-Induced Factor (HIF-1) mediates the cell’s response to reduced O2 
availability. Under hypoxic conditions, HIF-1 binds to the hypoxia response element of genes 
encoding for glucose transporters (GLUT 1 and 3) and most glycolytic enzymes activating their 
transcription (J. Kim, Tchernyshyov, Semenza, & Dang, 2006). O-GlcNAcylation stabilizes HIF-
1 and results in metabolic reprogramming in cancer cells, and high levels of HIF-1 are associated 
with elevated levels of OGT (Ferrer et al., 2014). 
 In addition to promoting cell proliferation, O-GlcNAcylation also increases migration 
and invasion of some types of cancer. For example, O-GlcNAcylation supports a fibroblast-like 
phenotype in a colorectal cancer cell line, and silencing of OGA affected the expression of genes 
associated with migration and growth (Chaiyawat, Netsirisawan, Svasti, & Champattanachai, 
2014). In the lung cancer cell line A549, transformation of cells to a more invasive phenotype 
was directly associated with activation of the HBP (Lucena et al., 2016). For cancer cells to 
metastasize from a primary tumor site, the cells undergo a transformation. This transformation is 
referred to as the epithelial-mesenchymal transition (EMT) because polarized epithelial cells, 
bound to the basement membrane, undergo biochemical and morphological transitions to become 
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more “mesenchymal like” in their phenotype. Mesenchymal cells have an increased ability to 
migrate and invade other tissues, are more resistant to apoptosis than epithelial cells, and have 
increased expression of extra cellular matrix  (ECM) proteins (Kalluri & Weinberg, 2009). One 
key feature of EMT is the notable switch of E-Cadherin vs. N-Cadherin protein expression, in 
which cells reduce the expression of the epithelial adhesion molecule, E-Cadherin, in favor of the 
expression of the mesenchymal adhesion molecule, N-Cadherin. The reduction in E-Cadherin 
expression is largely regulated by the transcription factor, Snail1, which is stabilized by O-
GlcNAcylation during hyperglycemic conditions (Sang Yoon Park et al., 2010). Additionally, 
the HBP is closely connected with several other pathways relevant to the EMT process, 
including Wnt (Wu et al., 2014; Zhou et al., 2016) and NOTCH (Taparra, Tran, & Zachara, 
2016). 
Importantly, O-GlcNAcylation influences many cancers of the female reproductive 
system. O-GlcNAcylation and OGT are both regularly elevated in breast and ovarian cancer 
(Trinca & Hagan, 2017), and both O-GlcNAc cycling enzymes are elevated in the leading edge 
of invasive endometrial tumors (Krześlak, Wójcik-Krowiranda, Forma, Bieńkiewicz, & Bryś, 
2012). In cervical cancer, O-GlcNAcylation has been shown to support tumorigenicity through 
the HPV genes E6 and E7 (M. Kim et al., 2016).   Among these examples, endometrial cancer is 
the most common cancer of the female reproductive tract. Women with Type 2 Diabetes (T2D) 
have a 2-3 fold increased risk for developing endometrial cancer compared to a metabolically 
healthy cohort (Friberg, Orsini, Mantzoros, & Wolk, 2007). This connection provides the 
motivation for studies of O-GlcNAc in models of endometrial cancer; however, the literature is 
wanting. Among the first few studies to make a connection between O-GlcNAc and endometrial 
cancer, in 2012 Krzeslak et al. found that O-GlcNAc cycling enzyme genes (OGT and MGEA5) 
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are upregulated along the myometrial-invading edge of endometrial tumors, suggesting a role for 
O-GlcNAcylation in metastasis (Krześlak et al., 2012). This discovery supported earlier work 
that noted a variation in the extent of O-GlcNAcylation between histological samples of non-
pathologic and pathologic endometrium as evaluated immunohistochemically (Sgantzos et al., 
2007). In 2016, Zhou et. al., determined that high glucose culture conditions impair Wnt 
signaling and increase the expression of the mesenchymal marker, β-catenin, in the endometrial 
cancer cell lines, AN3CA and HEC-1. Additional experiments using the OGA inhibitor, 
PUGNAc, revealed these outcomes resulted from increases in HBP activity and subsequent O-
GlcNAcylation (Zhou et al., 2016).  These observations suggest that O-GlcNAcylation plays a 
role in the development and progression of endometrial cancer.  
Unlike breast and endometrial cancer, obesity and diabetes are not considered leading 
risk factors for cervical cancer. However, the autoimmune disease, T1D evidently does double 
the risk for cervical cancer (Zendehdel, 2003). The leading cause of cervical cancer is infection 
by the human papilloma virus (HPV). There are more than 100 types of HPV, however, only a 
handful of these have been linked to cervical cancer, these are referred to as the high risk (HR) 
HPV’s. Most notably HR-HPV 16 and 18 are responsible for nearly 71% of all cervical cancer 
cases (Burd, 2003). Interestingly, OGT interacts with the HPV oncogenes E6 and E7 to promote 
tumorigenesis (M. Kim et al., 2016). Specifically, O-GlcNAcylation, and the expression of OGT 
and O-GlcNAcylated HCF-1 are all elevated in cervical cancers, which in turn promotes the 
transcription of E6/E7 oncogenes (M. Kim et al., 2016). A similar study corroborated these 
observations and also demonstrated that HPV E6 alone induces elevated O-GlcNAcylation (Zeng 
et al., 2016). While metabolism does not directly influence the risk of cervical cancer, changes in 
O-GlcNAcylation still have a significant impact on cell function and disease progression. 
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While insight into the role O-GlcNAcylation in the development and advancement of 
cancer has been attained in recent years, the field is still relatively new, and many questions 
remain unanswered, especially as they pertain to women’s cancers. The following chapters are 
dedicated to new discovery of the impact O-GlcNAcylation on the tumorigenic and metastatic 
potential of cervical and endometrial cancer. As is evident from the most current literature, these 
areas of cancer biology represent a new frontier that has not been previously explored.  
 
The Potential Link Between Dysregulation of O-linked β-N-acetylglucosamine (O-GlcNAc) 
Cycling And Tumorigenicity of Cancers of the Female Reproductive Tract 
 
Diabetes Mellitus is a major risk factor for cancer and continues to be a disease becoming 
more prevalent in today’s society. For instance, in 2012 there were 29.1 million Americans 
diagnosed with DM; with 1.4 million new cases diagnosed each year (Gallagher & LeRoith, 
2015). Of these cases, a shocking 208,000 patients were under the age of 20 (McCarthy, 2014). 
As DM affects more people and a higher percentage of youth, it is important that work continue 
toward understanding the mechanisms controlling this disease and its associated complications. 
In particular, DM associated with both cervical and endometrial cancer threatens the fertility of 
the next generation of reproductive-age individuals (Vrachnis et al., 2016). To date, the most 
effective, yet least desirable, form of treatment for these cancers is surgery; and while hormonal 
treatment is a fertility-sparing option (Kesterson & Fanning, 2012; Montz, Bristow, Bovicelli, 
Tomacruz, & Kurman, 2002), the possibility exists that diabetic complications may impact its 
effectiveness. Thus, an overarching goal of this study is to determine whether O-GlcNAc status 
and its manipulations affect the aggressiveness of cervical and endometrial cancers and how 
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hyper-O-GlcNAcylation may pre-dispose cells to metastasis.  Additionally, the question of how 
high levels of O-GlcNAcylation impact the effectiveness of progesterone treatment will be 
explored. Collectively, the work will provide insight about the mechanisms of metastasis in 
cancers of the female reproductive tract, which may in turn inform treatment protocols. 
Additionally, in the future, O-GlcNAcylation may serve as a biomarker for prognosis and 
treatment success, particularly in the context of individualized medicine in which coupling of 
dietary or metabolic treatment with current hormone-based methods may be beneficial to at-risk 
patients. 
Aims and Hypotheses 
Aim 1. Determine the effect of global O-GlcNAcylation on tumorigenic potential in cervical 
cancer (SiHa) cells. 
H1: Global O-GlcNAcylation supports proliferation of cervical cancer cells. 
H2: Global O-GlcNAcylation augments migration and invasion of cervical cancer cells. 
H3: Reduced O-GlcNAcylation increases susceptibility to cell-mediated death and alters 
the cytoskeleton.  
Aim 2.  Characterize the relationship between O-GlcNAcylation and Epithelial-
Mesenchymal Transition (EMT) in endometrial cancer. 
H1: Hyper-O-GlcNAcylation enhances the expression of EMT associated proteins. 




Aim 3. Determine the impact of Global Hyper-O-GlcNAcylation on the efficacy of 
progesterone treatment of endometrial cancer.  
H1: Hyper-O-GlcNAcylation impairs the anti-proliferative effects of progesterone 
treatment. 























ALLOXAN INDUCED HYPO-O-GLCNACYLATION IMPAIRS CERVICAL CANCER 













ALLOXAN INDUCED HYPO-O-GLCNACYLATION IMPAIRS CERVICAL CANCER 
CELL PROLIFERATION, INVASION, AND CYTOSKELETAL ORGANIZATION 
 
Introduction 
Cervical cancer is among the most common types of cancer world-wide, and is the most 
readily diagnosed form of cancer for women in developing countries (Vaccarella & Bray, 2015). 
Infection by human papillomavirus (HPV) is the primary cause of cervical cancer, with 
approximately 97% of all cervical cancer patients testing positive for HPV DNA (Munoz N, 
Bosch FX, de Sanjose S, Herrrero R, Castetellaasague X, 2003). Fifteen types of HPV are 
classified as high-risk (HR-HPV) based upon their prevalence and oncogenic nature (Munoz N, 
Bosch FX, de Sanjose S, Herrrero R, Castetellaasague X, 2003), with two types (HPV 16 and 18) 
being closely related and contributing to the majority of all cervical cancer tumors (Crow, 2012). 
In less-developed nations, cervical cancer continues to be the leading cause of cancer-related 
death in women (Crow, 2012; Woodman, Collins, & Young, 2007). Prophylactic measures to 
prevent cervical cancer in these parts of the world present logistical challenges, so there is 
increasing urgency to gain insight about disease progression and to develop therapeutic methods 
that will ultimately eliminate the problem.  
In many epithelial cancers, there is an increase in the post-translational modification of 
cellular proteins that includes β-N-acetylglucosaminylation (O-GlcNAcylation) (Fardini, 
Dehennaut, Lefebvre, & Issad, 2013; Ferrer, Sodi, & Reginato, 2016; Chad Slawson & Hart, 
2011). O-GlcNAcylation is a unique form of glycosylation that results in the addition of a single 
19 
 
sugar moiety, β-N-acetylglucosamine (GlcNAc), to proteins at serine and threonine residues. The 
enzyme, O-GlcNAc Transferase (OGT) adds O-GlcNAc to the proteins via the substrate UDP-
GlcNAc, the end product of the Hexosamine Biosynthesis Pathway (HBSP). Conversely, the 
enzyme O-GlcNAcase (OGA) removes O-GlcNAc from the targeted proteins (Bond & Hanover, 
2015). In this manner, the reversible and dynamic nature of O-GlcNAc modification is akin to 
phosphorylation of cellular proteins rather than simply glycosylation. Because O-GlcNAcylation 
occurs on serine and threonine residues it is also known to dynamically influence O-
phosphorylation (Comer & Hart, 2000). Proteins can be reciprocally modified by O-GlcNAc and 
O-phosphate (i.e., estrogen receptor β) (Cheng & Hart, 2000), while in other instances O-
GlcNAc physiologically competes with phosphorylation via steric hindrance (Ngoh, Facundo, 
Zafir, & Jones, 2010). Still other proteins, for example many cytokeratin intermediate filaments, 
exhibit both forms of modifications, but at distant sites (Hart et al., 2011). 
The primary cytokeratin heterodimer expressed in most simple epithelial cells is 
cytokeratin 8/18. The type I monomer, cytokeratin 18 (K18), is O-GlcNAcylated at three serine 
residues in the head domain, while still highly-phosphorylated in the tail domain (N.-O. Ku et al., 
2010; Omary, Ku, Tao, Toivola, & Liao, 2006). The major biological function of cytokeratin is 
structural, but K18 is also important in many cellular functions including apoptosis, mitosis, cell 
cycle progression, and cell signaling (Brian T. Sullivan, MS, Jessica A Cherry, MS, Hideo 
Sakamoto, PhD, Luiz E Henkes, PhD, David H. Townson, PhD, and Bo Rueda, 2010; Pan, 
Hobbs, & Coulombe, 2013; Yu-Rong Weng et al., 2012). Additionally, K18 is widely-used as a 
diagnostic tool and biomarker for many epithelial cancers (Fortier, Asselin, & Cadrin, 2013a; 
Toivola, Boor, Alam, & Strnad, 2015; Yu-Rong Weng et al., 2012), and is known to promote 
metastasis (Fortier et al., 2013a). Critically, the dynamic equilibrium of K8/18 filament stability 
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between soluble and filamentous forms is crucial in determining cellular function, and is 
regulated by both site specific phosphorylation and O-GlcNAcylation (Srikanth, Vaidya, & 
Kalraiya, 2010b). 
Acknowledging that high intracellular concentrations of O-GlcNAc and high levels of O-
GlcNAcylation are common among many cancers, the role of this form of glycosylation in 
disease progression remains poorly understood. There are a variety of endpoints to measure 
metastatic potential, but the extent to which O-GlcNAcylation impacts these measures in cervical 
cancer is in its infancy.  In the current study we investigated the impact of global O-
GlcNAcylation on cervical cancer cells, hypothesizing that it augments metastatic potential, in 
part by facilitating cytoskeletal re-organization. 
Materials and Methods 
Cell Culture and Reagents. The human cervical cancer cell line, SiHa (ATCC® HTB35™), 
derived from the cervical tumor of a HR-HPV 16-infected patient was used (Friedl, Kimura, 
Osato, & Ito, 1970). At present, there are no reports indicating the state of O-GlcNAcylation or 
other forms of glycosylation within this cell line. The SiHa cells were maintained in Eagle’s 
Minimum Essential Medium (EMEM) supplemented with 10% fetal bovine serum (FBS) and 
antibiotic-antimycotic purchased from Thermo Scientific (Waltham, MA) and cultured in a 
humidified 5% CO2 environment at 37°C. Achieving a relative state of hypo-O-GlcNAcylation 
was accomplished by exposing the cultures to the OGT inhibitor, Alloxan monohydrate (Konrad 
et al., 2002) (5mM) purchased from Sigma-Aldrich (St. Louis, MO) dissolved in DMSO 
(Thermo Fisher, Waltham, MA), for a period of 8-24 hours depending upon experimental 
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endpoints.  Additional SiHa cultures were exposed to an equivalent amount of DMSO (1μl/ml) 
as a negative control.  
Cell Proliferation Assay. In a set of 3 independent experiments, cells were seeded in flat-sided 
Thermo Scientific™ Nunc™ Cell Culture Tubes (Waltham, MA) at an initial seeding density of 
50k cells/ml of culture medium as described above. Treatment groups included cultures 
continuously exposed to vehicle (DMSO-Control) or 5mM Alloxan. The conditioned culture 
medium was exchanged daily, and the cells from one tube for each group were harvested for 
counting at 24-hour intervals for a total of seven days.                                                           
Caspase-Glo 3/7 Assay for Apoptosis. In a set of 3 independent experiments, cells were seeded 
into 96-well plates (Corning™ Costar™ 96-Well White Clear-Bottom Plates) at a density of 
20,000 per well in 100μL of complete media, as described above, for 24 hours. Conditioned 
medium was then exchanged with fresh medium, now containing 1% FBS, and without/with 
Alloxan (5mM) for 8hrs. The cells were then pre-treated for one hour with the protein synthesis 
inhibitor, 30µg/ml Cycloheximide (CHX; Sigma-Aldrich), followed by a 10µl spike of either 
10µg/ml TNF-alpha (R&D Systems), 1µg/ml Fas-L antibody (CH11; EMD Millipore), or 10µM 
Staurosporine (Sigma-Aldrich) for 7.5 hours. Incidence of apoptosis was determined by 
measuring caspase activity according to the manufacturer’s recommendations (Caspase-glo 3/7 
Assay; Promega, Madison, WI).                                                                                                                      
Cell Migration Invasion Assay. Three independent  in vitro cell migration-invasion 
experiments were conducted to measure metastatic potential of the SiHa cells as described in 
similar experiments (Hu & Verkman, 2006; Kramer et al., 2013; Qian et al., 2012). Briefly, the 
assays were conducted using Corning® Transwell® polycarbonate membrane cell culture inserts 
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for 12 well plates (VWR, Radnor, PA) containing a Tissue Culture-treated polycarbonate 
membrane filter (6.5mm diameter, 8μm pore size). The upper chamber of each well contained 
the SiHa cell suspension (50K cells/well) in serum-free medium, and the lower chamber 
contained medium supplemented without/with 10% FBS (chemoattractant). After 6, 12, and 24 
hours of incubation at 37°C and 5% CO2, the cells on the top of the membrane (non-invasive) 
were removed with a cotton swab, and the inserts were fixed and stained with 250μls of crystal 
violet (Thermo Scientific, Waltham, MA).  Invasive cells were photographed (200X 
magnification) and quantified for 3 random fields (200X magnification) per insert.  Relative 
migration was calculated by dividing the average number of cells/field by the area of the 
microscope viewing field (0.011cm2) and then multiply this number by the entire area of the 
Transwell insert (0.3 cm2). Percent invasive was then calculated by dividing this by the number 
of cells initially seeded in the inserts (50k cells) as described in the manufacturer’s protocol.  
Migration Wound Healing Assay. To confirm and complement the results of the migration-
invasion assay, an in vitro wound healing assay was used to assess metastatic potential of the 
SiHa cells, as described for other types of metastatic cells in the literature (Hu & Verkman, 2006; 
Kramer et al., 2013; Moy et al., 2014). In a set of three independent experiments, cells were 
cultured to confluency in 24 well plates (Thermo Fisher) as described above.  The monolayers of 
cells were then washed twice to remove non-adherent cells, and “wounded” using a small cell 
scraper (Thermo Fisher, cat# 08-100-241) to induce a linear, 4mm-wide wound.  The culture 
medium was exchanged every 24 hours and Alloxan treatment was maintained throughout the 
experiment. At 24 hour intervals, the cells were fixed and stained with crystal violet, and 
photographed. Closure of the wound was calculated as a percentage of the total open area and 
cell migration rate was calculated as area closed divided by time.  
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Immunofluorescent Staining. The effect of global O-GlcNAcylation on the stability of K8/18 
filaments in SiHa cells was evaluated immunocytochemically.  Briefly, SiHa cells were grown 
on 0.1N HCl-treated coverslips for 24 hours and then treated without/with Alloxan for 8hrs. The 
cells were washed three times with washing buffer (PBS with 0.1% BSA) and sequentially fixed 
for 10 minutes using 100% ice-cold methanol for 10 minutes and blocked for 24 hours with 10% 
normal goat serum in 0.1% BSA and phosphate buffered saline.  Cells were then incubated for 
24 hours at 4°C in primary antibody (anti-human keratin 18 monoclonal antibody, clone CY90, 
1:500 dilution; Sigma, St. Lois, MO). Following primary incubation, the cells were then washed 
with washing buffer  and incubated for one hour at room temperature in detection antibody 
(rabbit anti-mouse IgG conjugated with Alexa-488, 1:1000 dilution; Life Technologies, St. Lois, 
MO). The cells were counterstained and mounted to slides using ProLong Gold Antifade 





















Figure 1: Cell proliferation was impaired by the loss of O-GlcNAcylation (Alloxan) (p<0.0001). 
Total number of generations, multiplication rate, and generation time for Control versus O-
GlcNAc-inhibited cells was 2.2 vs. 0.6 generations, 0.4 vs. 0.1 doublings per day, and 2.35 vs. 
































Figure 2: [A] Representative images of cell migration from three independent migration 
invasion experiments. [B] Percent migration was calculated by dividing the invasive population 
(determined by counting 3 random fields) by the number of cells seeded. Invasion was impaired 
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Figure 3: Representative images of cell migration from three independent wound healing assays. 
Inhibition of O-GlcNAcylation reduced the migration rate (P<0.001), and thus the wound healing 
potential of the SiHa cells. The migrated surface area and migration rate for control vs. O-
GlcNAcylation inhibited (Alloxan-treated) cells was 5.5 vs. 4.1 mm2, and 5.5 vs. 4.1μm/hour 
respectively. Full wound closure was achieved in control cultures by 120 hours, whereas O-
GlcNAcylation inhibited cultures did not reach 100% confluency until 168 hours.    
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Figure 4: Immunofluorescent staining of the keratin 8/18 filament network suggests a reduction 
in K18 expression in Hypo-O-GlcNAcylated cells. Keratin 18 also appears to be more granular 
(soluble) in treated cells compared to the filamentous staining seen in control cells. 
 
Figure 5: Both control cells (vehicle) and hypo-O-GlcNAcylated (ALX) cells responded to 
cytokine treatment (P<0.05). However, reduced O-GlcNAcylation increased SiHa cells 







































Hypo-O-GlcNAcylation impairs cervical cancer cell proliferation, invasion, and migration 
Studies of the similar cervical cancer cell line (HeLa), have shown defects in G1 
progression following treatment with the GFAT1 inhibitor, DON, to reduce global O-
GlcNAcylation (Chad Slawson et al., 2005). However, the same study also found increased O-
GlcNAcylation to cause changes to the cell cycle, possibly through the induced changes to OGT 
and OGA expression. Low glucose conditions were also found to down-regulate Sp1 activity 
through hyper-O-GlcNAcylation as opposed to hypo-O-GlcNAcylation in the same cell line 
(Kang, Ju, Cho, & Hwang, 2003). More consistently, hyper-O-GlcNAcylation has been 
implicated in increased proliferation in both breast (Chaiyawat et al., 2014) and ovarian cancer 
(Kwei, Baker, & Pelham, 2012). These findings illuminate the complex nature of O-
GlcNAcylation and highlight its role as nutrient sensor, but do not address the effects of OGT 
inhibition, directly. And with recent scrutiny of the reliability of the HeLa cell as a model for 
cervical cancer, we felt repeating proliferation studies in a new cell line to be of importance. 
SiHa cell proliferation was assessed monitoring growth curves through the death phase in 
control cultures (~120 hours; Figure 1).  The lack of O-GlcNAcylation (Hypo-O-GlcNAc) 
impaired SiHa cell proliferation (p<0.0001) compared to control cultures over the entire length 
of the experiment. SiHa cells in control cultures grew an average of 2.2 (+/- 0.96) generations 
with an average generation time of 2.5 (+/- 0.12) days (Figure 1).  Conversely, Hypo-O-
GlcNAcylated SiHa cells did not double at all in culture and the generation time extended 
beyond the seven days of the experiment.  Overall, the doubling rate for controls was four-fold 
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higher per day than the Hypo-O-GlcNAcylated cultures (0.4 vs 0.1; p<0.0001) when averaged 
across the experiment.  Notably, while proliferation rate was significantly impaired by the loss of 
O-GlcNAcylation, viability of the SiHa cells was unaffected; viability in both treatment groups 
was ~95% as determined by Trypan blue exclusion (results not shown). These results implicate 
O-GlcNAcylation as an important regulator of the cell cycle, as concluded in the above 
mentioned studies. More specifically, inhibition of OGT has a negative effect on proliferation, 
and future studies should focus on the mechanisms responsible.  
Observing that O-GlcNAcylation impaired cell proliferation but not viability, we then 
investigated the effect of this post-translational modification on aspects of cellular metastasis of 
SiHa cells by measuring relative invasiveness and migration potential. Both global and specific 
protein and transcription factor O-GlcNAcylation has been linked to increased 
migration/invasion in both breast (Sa Caldwell et al., 2010; Huang et al., 2013) and ovarian 
cancer (F. Jin, Yu, Zhao, Wu, & Yang, 2013). O-GlcNAc cycling enzymes are also known to be 
up-regulated in the myometrial invasive cells of endometrial cancer (Krześlak et al., 2012). In 
this way, our findings are consistent with the literature in similar tissue types. Control cultures of 
SiHa cells displayed an aggressive phenotype, characterized by cell penetration through the 
Transwell® polycarbonate membrane insert within 6 hours of culture (Figure 2).  The extent of 
cell penetration increased linearly over the next 12 hours and then plateaued at 24 hours (Figure 
2B).  For purposes of comparison, the 24 hour endpoint was selected to further evaluate SiHa 
cell invasiveness in Control and Hypo-O-GlcNAc cultures for this study.  Hypo-O-
GlcNAcylation reduced cell invasion compared to controls as depicted in Figure 2 (p<0.05), 
suggesting that GlcNAcylation influences the mobility of the cells.  A wound-healing assay, 
which evaluates cell migration, was conducted to corroborate this. Hypo-O-GlcNAcylation also 
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impaired the migration potential of SiHa cells compared to control, as evidenced by a larger 
wound area (55mm2 vs. 4.1mm2) for Hypo vs. control, respectively, P<0.001), 48 hours after 
wound creation (Figure 3). This inability of Hypo cells to accomplish wound closure extended 
beyond 96 hours of culture, wherein only 60% wound closure was achieved at this time point 
(Figure 3). 
O-GlcNAcylation may stabilize K18 filaments resulting in increased cell survival 
Morphological differences were observed between SiHa cells grown under control 
conditions and those in which O-GlcNAcylation is impaired. Hypo-O-GlcNAcylated cells 
showed a decrease in cytoplasmic area and were more spindle-like in shape compared to 
normally glycosylated cells. To further investigate this observation, cells were grown on 
coverslips, fixed, and stained for cytokeratin 18 (figure 4), the main cytokeratin expressed in the 
cervix. K18 decreased in perinuclear localization and increased in aggregation. Representative 
images from 4 independent experiments suggest hypo-O-GlcNAcylated cells exhibit a change in 
K18 organization. Control cells exhibited a filamentous K18 network, while those of the hypo-
O-GlcNAcylated cells were granular, suggesting increased solubility, which is consistent with 
findings in human hepatocytes, where K8/18 is the sole intermediate filament (Srikanth et al., 
2010b). 
K18 expression has been implicated in cell survival mechanisms in hepatocytes (N.-O. 
Ku et al., 2010) and granulosa cells (Trisdale, Schwab, Hou, Davis, & Townson, 2016), and 
previous research conducted with HeLa cells indicated K18 filaments were protective against 
Fas-mediated apoptosis (Brian T. Sullivan, MS, Jessica A Cherry, MS, Hideo Sakamoto, PhD, 
Luiz E Henkes, PhD, David H. Townson, PhD, and Bo Rueda, 2010). The current study saw a 
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similar increase in susceptibility to FasL in the presence of an OGT inhibitor (figure 5), but no 
increase in susceptibility to TNF-α. These results are congruent with studies on hepatocytes that 
found disruption of K8/18 filaments by a point mutation resulted in increased susceptibility to 
Fas-induced, but not TNF-induced apoptosis (N. O. Ku, Soetikno, & Omary, 2003). This 
supports the hypothesis that O-GlcNAcylation stabilizes K18 filaments in cervical cancer cells, 
affording cell survival mechanisms. 
Conclusion 
O-GlcNAcylation of cervical cancer cells augments tumorigenicity by improving cell 
proliferation rate, migration and invasion potential. Additionally, a reduction of O-
GlcNAcylation resulted in increased solubility of cytokeratin 18 and subsequently, an increased 
susceptibility to Fas-mediated cell death. This work suggests a connection between expression of 
K18 and O-GlcNAcylation levels in several tumorigenic mechanisms of cervical cancer and 
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O-GLCNACYLATION ENHANCES THE TUMORIGENIC PROPERTIES OF CERVICAL 
CANCER CELLS IN VITRO 
Introduction 
Cervical cancer is among the most common types of cancer world-wide, and is the most 
readily diagnosed form of cancer for women in developing countries (Vaccarella & Bray, 2015). 
Infection by human papillomavirus (HPV) is the primary cause of cervical cancer, with 
approximately 97% of all cervical cancer patients testing positive for HPV DNA (Munoz N, 
Bosch FX, de Sanjose S, Herrrero R, Castetellaasague X, 2003). Fifteen types of HPV are 
classified as high-risk (HR-HPV) based upon their prevalence and oncogenic nature (Munoz N, 
Bosch FX, de Sanjose S, Herrrero R, Castetellaasague X, 2003), with two types (HPV 16 and 18) 
being closely related and contributing to the majority of all cervical cancer tumors (Crow, 2012). 
In less-developed nations, cervical cancer continues to be the leading cause of cancer-related 
death in women (Crow, 2012; Woodman et al., 2007). Prophylactic measures to prevent cervical 
cancer in these parts of the world present logistical challenges, so there is increasing urgency to 
gain fundamental insight about disease progression and to develop therapeutic methods that will 
ultimately eliminate the problem.  
In many epithelial cancers, disease onset and progression are associated with  increases in 
post-translational modification of cellular proteins, including β-N-acetylglucosaminylation (O-
GlcNAcylation) (Fardini et al., 2013; Z. Ma & Vosseller, 2013; Chad Slawson & Hart, 2011). O-
GlcNAcylation is a unique form of glycosylation that results in the addition of a single sugar 
moiety, β-N-acetylglucosamine (GlcNAc), to proteins at serine and threonine residues. The 
enzyme, O-GlcNAc Transferase (OGT) adds O-GlcNAc to the proteins via the substrate UDP-
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GlcNAc, the end-product of the hexosamine biosynthesis pathway (HBSP). Conversely, the 
enzyme O-GlcNAcase (OGA) removes O-GlcNAc from the targeted proteins (Bond & Hanover, 
2015). In this manner, the reversible and dynamic nature of O-GlcNAc modification is akin to 
phosphorylation of cellular proteins rather than simply glycosylation. Because O-GlcNAcylation 
occurs on serine and threonine residues, it can dynamically influence O-phosphorylation (Comer 
& Hart, 2000). Proteins can be reciprocally modified by O-GlcNAc and O-phosphate (e.g., 
estrogen receptor β (Cheng & Hart, 2000)), while in other instances O-GlcNAc competes with 
phosphorylation physiologically via steric hindrance (Ngoh et al., 2010). Still other proteins, for 
example many cytokeratin intermediate filaments, exhibit both forms of modifications, but at 
distant sites (Hart et al., 2011). 
The most common type of cytokeratin intermediate filament expressed in simple 
epithelial cells is the heterodimer, cytokeratin 8/18 (K8/18). The type I monomer, cytokeratin 18 
(K18), is O-GlcNAcylated at three serine residues in the head domain, while still highly-
phosphorylated in the tail domain (N.-O. Ku et al., 2010; Omary et al., 2006). The major 
biological function of cytokeratins is structural, but K8/18 filaments are also important in many 
cellular functions including apoptosis, mitosis, cell cycle progression, and cell signaling (Brian 
T. Sullivan, MS, Jessica A Cherry, MS, Hideo Sakamoto, PhD, Luiz E Henkes, PhD, David H. 
Townson, PhD, and Bo Rueda, 2010; Pan et al., 2013; Y.-R. Weng, Cui, & Fang, 2012). 
Additionally, K18 of K8/18 filaments is widely-used as a diagnostic tool and biomarker for 
many epithelial cancers (Fortier, Asselin, & Cadrin, 2013b; Toivola et al., 2015; Y.-R. Weng et 
al., 2012), and is known to promote metastasis (Fortier et al., 2013b).  Importantly, the dynamic 
equilibrium of K8/18 filament stability between soluble and filamentous forms is crucial in 
35 
 
determining cellular function, and this stability is regulated by both site-specific phosphorylation 
and O-GlcNAcylation (Srikanth et al., 2010a). 
High intracellular concentrations of O-GlcNAc and high levels of O-GlcNAcylation are 
common among many cancers, yet the role of this form of glycosylation in disease progression is 
less understood. Additionally, there are a variety of endpoints to measure metastatic potential, 
but the extent to which O-GlcNAcylation impacts these measures in cervical cancer is unknown.  
The objective of the current study was to investigate the impact of global O-GlcNAcylation on 
cervical cancer cells, hypothesizing that O-GlcNAcylation augments metastatic potential, in part 
by influencing K8/18 filaments and cytoskeletal re-organization. 
Materials and Methods 
Cell Culture and Reagents. The human cervical cancer cell line, SiHa (ATCC® HTB35™), 
derived from the cervical tumor of a HR-HPV 16-infected patient was used (Friedl et al., 1970). 
At present, there is no information available indicating the state of O-GlcNAcylation or other 
forms of glycosylation within this cell line. For culture, the SiHa cells were maintained in 
Eagle’s Minimum Essential Medium (EMEM), supplemented with 10% fetal bovine serum 
(FBS) and antibiotic-antimycotic, all purchased from Thermo Fisher Scientific (Waltham, MA).  
The cells were incubated in a humidified, 5% CO2 environment at 37°C. Global inhibition of O-
GlcNAcylation (Hypo- O-GlcNAcylation) was achieved by exposing the cells to the OGT 
inhibitor, OSMI-1 (50μM) as described previously by others (M. Kim et al., 2016; Ortiz-Meoz et 
al., 2015), and was verified by immunoblotting (described below).  The OSMI-1 was purchased 
from Aobious (Gloucester, MA) dissolved in DMSO (Thermo Fisher), and the cells were 
exposed for a period of 9-24 hours depending upon the experimental endpoint (described below).  
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Additional cultures of SiHa cells were exposed to an equivalent amount of DMSO (1μl/ml) as a 
negative control.  
Immunoblotting for Global O-GlcNAcylation. Whole cell lysates of SiHa cells cultured in 
25cm2 flasks (Corning, Corning, NY) for 48 hours, were harvested by scraping, and separated on 
pre-stained SDS-Page gels (BioRad, Hercules, CA) and transferred to PVDF membrane. 
Membranes were then probed for global O-GlcNAcylation (CST-O-GlcNAc 110.6 antibody; 
Cell Signaling Technology, Inc.; Beverly, MA) and then secondary antibody (Anti-rabbit IgG 
HRP-linked Antibody, Cell Signaling Technology, Inc.), followed by Clarity Western ECL 
substrate (BioRad). Blots were imaged on the BioRad ChemiDoc Imaging System.  
Cell Proliferation Assay. In a set of 3 independent experiments, cells were seeded in duplicate 
in flat-sided Thermo Fisher Scientific™ Nunc™ Cell Culture Tubes at an initial seeding density 
of 60k cells/ml of culture medium. Treatment groups included cultures of cells continuously 
exposed to vehicle (DMSO-Control) or 50μM OSMI-1. The conditioned culture medium was 
exchanged without/with treatment daily, and the cells for each group were harvested for counting 
at 24-hour intervals over a seven-day period.  
Flow Cytometric Analysis of Cell Cycle Progression. In a set of 3 independent experiments, 
SiHa cells were seeded at a density of 100,000 cells/ml in T-25 flasks (Corning) and treated 
without or with OSMI-1 in culture through the exponential growth phase before being 
enzymatically harvested and fixed/permeabilized with 70% ethanol. The cells were then stained 
with propidium iodide (PI) and fluorescence was measured with a 488nm laser (610/20 BP 
Filter) on a BD LSRII Flow Cytometer. Data were analyzed with Flow Jo Analysis Software.  
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Caspase-Glo 3/7 Assay for Fas-Induced Apoptosis. In a set of 3 independent experiments, 
SiHa cells were seeded in triplicate into 96-well plates (Corning™ Costar™ 96-Well White 
Clear-Bottom Plates) at a density of 20,000 per well in 100μL of complete media and then 
cultured without or with OSMI-1 (50 µM) for 24 hours. The cells were then pretreated for 30 
min with the protein synthesis inhibitor, 30µg/ml Cycloheximide (CHX; Sigma-Aldrich), 
followed by 1µg/ml Fas-L antibody (CH11; EMD Millipore), or 10µM Staurosporine (Sigma-
Aldrich) for 8 hours. The incidence of apoptosis was determined using a caspase enzyme assay, 
following the manufacturer’s recommendations (Caspase-Glo 3/7 Assay; Promega, Madison, 
WI).                                                                                                
Cell Migration Invasion Assay. Three independent in vitro cell migration-invasion experiments 
were conducted to measure metastatic potential of the SiHa cells.  The assays were conducted 
using Corning® Transwell® polycarbonate membrane cell culture inserts for 24 well plates 
(VWR, Radnor, PA) containing a Tissue Culture-treated polycarbonate membrane filter (6.5mm 
diameter, 8μm pore size).  This approach has been described previously by others in similar 
experiments (Hu & Verkman, 2006; Kramer et al., 2013; Qian et al., 2012).   Briefly, the upper 
chamber of each well was seeded with SiHa cells (50K cells/well) in serum-free medium without 
or with OSMI-1 (50 µM) and the lower chamber contained medium supplemented without or 
with 10% FBS (chemoattractant). Treatments for each experiment were conducted in triplicate. 
After 24 hours of incubation at 37°C and 5% CO2, the cells on the top of the membrane (non-
invasive) were removed with a cotton swab, and the inserts were fixed and stained with 600μl of 
crystal violet (Thermo Scientific).  Invasive cells that had penetrated the membrane were 
photographed (20X magnification). Invasiveness was also quantified by de-staining the 
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membranes in 600ul of 70% ethanol for 10 minutes and then measuring the absorbance at 
540nm. 
Immunocytochemistry of Cytoskeletal Proteins. SiHa cells were cultured in 12 well plates 
(100K cells/well) on glass cover slips using conditions described above for 24 hours, then fixed 
and permeabilized with 100% methanol. Primary antibodies for the detection of K18 in the 
K8/18 filaments (CY90 antibody, Cell Signaling Technology, Inc.), α-tubulin (236-10501 
antibody, Thermo Fisher Scientific, Waltham, MA), and β-actin (13E5 antibody, Cell Signaling 
Technology, Inc.) were applied, followed by wash steps and detection using the secondary 
antibody (Anti-rabbit or IgG, HRP-linked Antibody, Cell Signaling Technologies) and AEC 
substrate kit (Vector Laboratories, Burlingame, CA).  The cells were counterstained with 
hematoxylin (Vector), mounted onto slides, and imaged at 40X.  
Statistical Analysis. All experiments were independently repeated a minimum of three times, 
using a fresh aliquot of SiHa cells (passage 4-7) to initiate each experiment. Data were analyzed 
by one- or two-way analysis of variance (ANOVA), followed by a Student’s t post-test for 










Figure 1. Inhibition of global O-GlcNAcylation by OSMI-1. [A] Immunoblot analysis of global 
O-GlcNAc in SiHa whole cell lysates following treatment with OSMI-1 for 4 and 24 hours. O-
GlcNAcylation of cellular proteins declined within 4 hours of OSMI-1 treatment and remained 
diminished through 24 hours.  There was no effect of OSMI-1 on total protein expression, as 
indicated in the lower panel [B] Impaired O-GlcNAcylation was also evident in fixed, cultured 
cells, wherein immunostaining for O-GlcNAcylation was reduced throughout the cytoplasm of 


















Figure 2. SiHa cell proliferation is impaired by Hypo-O-GlcNAcylation. [A] SiHa cell 
proliferation was impaired (p<0.01) by Hypo-O-GlcNAcylation following OSMI-1 exposure. 
Total number of generations, multiplication rate, and generation time for control versus Hypo-O-
GlcNAcylated cells were all reduced following 3 independent experiments. [B] Flow cytometric 
analysis of parameters of cell cycle progression revealed no effect of Hypo-O-GlcNAcylation 



















Figure 3.  Effect of Hypo-O-GlcNAcylation on SiHa cell invasion. [A] Representative images 
(10X) depicting SiHa cells that have penetrated the Transwell inserts in response to 
chemoattractant.  Note that OSMI-1 treatment impaired cell penetration. [B] A bar graph 
comparing the invasiveness of SiHa cells in control and Hypo-O-GlcNAcylated cultures for 3 





















Figure 4. Effects of Hypo-O-GlcNAcylation on SiHa cell morphology and cytoskeletal 
expression.  Representative images (40X) of immunocytochemical staining for keratin 18, α-
tubulin, and β-actin in SiHa cells are shown. Hypo-O-GlcNAcylation reduced both Keratin 18 and 
β-actin expression. There were no obvious alterations of α-tubulin expression observed. These 












Figure 5: Effect of Hypo-O-GlcNAcylation on SiHa cell sensitivity to apoptosis. A bar graph 
depicts the relative sensitivity of SiHa cells (Mean ±SEM) to cytokine- (Fas-L) and 
chemotherapeutic- (Staurosporine) induced apoptosis (as measured by cleaved caspase 3/7 
activity) following three independent experiments. Cytokine in the presence of the protein 
synthesis inhibitor, cycloheximide (CHX), induced apoptosis (p<0.05), but impairment of O-
GlcNAcylation did alter the sensitivity of the cells to FasL. Staurosporine was used as the positive 
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Hypo-O-GlcNAcylation of SiHa cells impairs cell proliferation and invasion 
A variety of studies have demonstrated that the state of global O-GlcNAcylation in cells, 
including epithelial-derived cancer cells, can have profound physiological effects on growth and 
development. In the current study, the effect of global O-GlcNAcylation on proliferation, 
invasion, and cytoskeletal organization was assessed in a cervical cancer cell line (SiHa cells).  
To our knowledge, this is the first report of the effects of the highly-specific O-GlcNAc 
Transferase (OGT) inhibitor, OSMI-1, on cervical cancer cells.  The ability of OSMI-1 to 
globally impair O-GlcNAcylation, without affecting SiHa cell viability, was clearly evident in 
these experiments, and was sustained for an extended period (Figure 1). Cell proliferation was 
assessed by monitoring growth curves through the death phase, and revealed that the lack of O-
GlcNAcylation (Hypo-O-GlcNAc) impaired proliferation (p<0.01) over the entire length of the 
experiment (Figure 2A). Overall, the doubling rate for controls was more than three-fold higher 
per day than the Hypo-O-GlcNAcylated cultures (0.7 vs 0.2; p<0.01) when averaged across the 
experiment. These results suggest O-GlcNAcylation regulates mitosis, possibly via the cell cycle 
(Chad Slawson et al., 2005).  Indeed, others have reported the cell cycle is accelerated (G1S) 
following exposure to the GFAT1 inhibitor, DON, which reduces global O-GlcNAcylation (Sa 
Caldwell et al., 2010); whereas the same study determined that increased O-GlcNAcylation 
delays G2/M progression, possibly through induced changes to OGT and OGA activity.  These 
findings illuminate the complex, sometimes unpredictable, nature of O-GlcNAcylation in cells.  
In the current study, however, hypo-O-GlcNAcylation via OSMI-1 had no effect on parameters 
of cell cycle progression (Figure 2B), indicating that SiHa proliferation is impaired in some other 
way.   
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Observing that hypo-O-GlcNAcylation impaired cell proliferation, but not viability, we 
then investigated the effect of this post-translational modification on aspects of cellular 
metastasis by evaluating the relative invasiveness of SiHa cells. Both global and specific O-
GlcNAcylation of proteins and transcription factors are linked to increased cell 
invasiveness/migration in breast and ovarian cancers (Huang et al., 2013; F.-Z. Jin, Yu, Zhao, 
Wu, & Yang, 2013; Steenackers et al., 2016). Similarly, upregulation of O-GlcNAc enzymes is 
associated with myometrial invasive cells in endometrial cancer (Krześlak et al., 2012). Our 
results are consistent with these findings. Control cultures of SiHa cells exhibited an aggressive 
phenotype, characterized by cell penetration through the Transwell® polycarbonate membrane 
insert within 24 hours of culture (Figure 3A). Conversely, hypo-O-GlcNAcylation reduced cell 
invasion (p<0.05; Figure 3B), suggesting that O-GlcNAcylation augments the mobility of the 
cells. Overall, the results indicate that O-GlcNAcylation, specifically through the actions of 
OGT, heightens the tumorigenic potential of cervical cancer cells by accelerating both 
proliferation and invasion capabilities. These observations agree with a recent study of OGT 
manipulation in colon cancer cell lines, wherein genetic silencing of OGT impaired cell 
invasiveness and migration (Steenackers et al., 2016). 
Hypo-O-GlcNAcylation affects cytoskeletal morphology, but not Fas-induced apoptosis 
Cytoskeletal proteins are fertile targets for post-translational modification, including O-
GlcNAcylation, so it is plausible for O-GlcNAcylation to affect cell morphology.  Indeed, SiHa 
cells exhibited pronounced changes in morphology following OSMI-1 treatment compared to 
control cells (Figure 4). Notably, immunostaining for K18 and β-actin proteins was diminished 
in Hypo-O-GlcNAcylated cells, and the cells generally had a flattened, stellate morphology 
compared to the more spindle-like appearance of control cells (Figure 4).  For K18, in particular, 
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staining was uniformly detectable throughout the cytoplasm in control cells; whereas it remained 
primarily perinuclear, and somewhat aggregated as it extended to the periphery in Hypo-O-
GlcNAcylated cells (Figure 4).  Similar forms of filament reorganization have been noted in 
other epithelial cancers (Busch et al., n.d.), and are believed to be a direct result of K8 
phosphorylation in K8/18 filaments (Fois, Weimer, Busch, & Felder, 2013).  In the current study, 
there was no evidence that α-tubulin expression was affected by hypo-O-GlycNAcylation 
(Figure 4), despite the observation that K18 and β-actin expression were both diminished. Others 
have observed that α-tubulin and β-actin expression in colon cancer cells are unaffected by 
inhibition of OGT, yet the morphology of these cells is “stocky and stunted” (Steenackers et al., 
2016).  Although K8/18 filament expression was not evaluated, the results of the previous study 
did support the concept that hypo-O-GlcNAcylation disrupts cytoskeletal organization.  Beyond 
a structural role, K8/18 filaments also influence cell survival, specifically providing resistance to 
Fas-induced apoptosis (Brian T. Sullivan, MS, Jessica A Cherry, MS, Hideo Sakamoto, PhD, 
Luiz E Henkes, PhD, David H. Townson, PhD, and Bo Rueda, 2010; N.-O. Ku et al., 2010; 
Trisdale et al., 2016).  In the present study, we found that SiHa cells are indeed resistant to Fas-
induced apoptosis, but such resistance is not influenced by hypo-O-GlyNAcylation (Figure 5; 
p>0.05), or associated with a loss of K8/18 filament expression (Figure 4).  This suggests the 
mechanism(s) of Fas-resistance in SiHa cells involve processes other than O-GlyNAcylation and 
proteins other than K8/18 filaments. Additionally, as noted above, the overall viability of the 
SiHa cells remained unaffected by hypo-O-GlyNAcylation, as measured by caspase 3/7 enzyme 
activity (Figure 5; Control vs. Hypo-O-GlycNAcylated, p>0.05).  Thus while other 
investigations have concluded O-GlcNAcylation is fundamental to cell viability, especially in 
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embryonic stem cells (Shafi et al., n.d.), the extent of impairment of O-GlcNAcylation in the 
current study was insufficient to hinder cell survival. 
Conclusion 
Overall, O-GlcNAcylation enhances the tumorigenic properties of SiHa cells by 
accelerating cell proliferation and augmenting invasive and migratory capabilities.  Conversely, 
hypo-O-GlcNAcylation alters cellular morphology and cytoskeletal organization, in part by 
reducing the expression of K8/18 and β-actin filament proteins.  The results support the 
hypothesis that O-GlcNAcylation augments metastatic potential of cervical cancer cells and 
suggest there is a physiologic connection between O-GlcNAcylation and cytoskeletal 
reorganization, ostensibly involving the modulation of O-phosphorylation of K8/18 filaments, 
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HYPER-O-GLCNACYLATION PROMOTES EPITHELIAL-MESENCHYMAL 
TRANSITION IN ENDOMETRIAL CANCER CELLS 
 
Introduction 
β-N-acetylglucosaminylation (O-GlcNAcylation) is a unique form of glycosylation that 
occurs on serine and threonine residues of proteins throughout the cytoplasmic and nuclear 
compartment of cells. It is a monosaccharide that is dynamically cycled akin to that of O-
phosphorylation. The enzyme O-GlcNAc transferase (OGT) adds O-GlcNAc to proteins via the 
substrate UDP-GlcNAc, while O-GlcNAcase (OGA) is responsible for its removal. O-GlcNAc 
influences the extent of O-phosphorylation of proteins through shared binding sites and steric 
hindrance (Bond & Hanover, 2015). As the end-product of the Hexosamine Biosynthesis 
pathway (HBP), UDP-GlcNAc and subsequent O-GlcNAcylation is considered a nutrient sensor 
to the overall metabolic status of the cell. Two to five percent of the glucose that enters the cell is 
channeled into the HBP.  As such, it is not surprising that increased O-GlcNAcylation is 
implicated in the development of insulin resistance (T Issad, Masson, & Pagesy, 2010). Aberrant 
O-GlcNAcylation is a characteristic of heart disease, neurodegenerative disorders such as 
Alzheimer’s disease, and is a hallmark of many cancers, including endometrial cancer (Krześlak 
et al., 2012). A relationship between glycosylation and metastasis is also evident in lung cancers, 
wherein epithelial-mesenchymal transition (EMT) acts through the HBP as an inducer of 
aberrant glycosylation (Lucena et al., 2016). Despite these observations, very little is known 
about the mechanistic actions of O-GlcNAcylation in cancer, specifically, in the EMT process.  
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Many illnesses associated with aberrant O-GlcNAcylation are also co-morbidities of 
Type 2 Diabetes (T2D). For instance, women with T2D have a 2-fold  greater risk of developing 
endometrial cancer than their healthy cohorts (Friberg et al., 2007). While the incidence of many 
forms of cancer is declining, endometrial cancer remains among those increasing for all women 
(Cote, Ruterbusch, Olson, Lu, & Ali-Fehmi, 2015). Endometrial cancer results from the 
abnormal growth, migration, and invasion of cells that line the uterus. Common genetic 
alterations in endometrial tumors include PTEN, PIK3CA, CTNNB1 (beta-catenin), and KRAS, 
all of which are related to metabolism (Byrne et al., 2014).  Moreover, all of these genes 
influence epithelial-mesenchymal transition (EMT) signaling pathways, and  recent studies 
indicate that the  E-cadherin repressors Slug, ZEB1, and HMGA2 are preferentially expressed 
along the myometrial invasive edge of tumors (Stewart & Mccluggage, 2013). Snail1, a key 
regulator of EMT, is stabilized by O-GlcNAcylation in several cell types (Sang Yoon Park et al., 
2010), and the mRNA of  O-GlcNAc cycling enzymes (OGT and OGA) is up-regulated in 
endometrial tumors(Krześlak et al., 2012), suggesting that O-GlcNAcylation influences 
metastasis.  
The gold standard for treatment of endometrial cancer is radiation therapy and surgery; 
however, 5-30% of women with endometrial cancer are premenopausal and under the age of 50 
at the time of diagnosis. For these women, fertility-sparing treatments, such as progestin therapy, 
are an option (Jeong-Yeol Park, 2015). A recent meta-analysis determined that women treated 
with hormonal therapy methods had a pooled regression rate of 76.2%, with 28% live births 
reported; however, a 40.6% relapse rate was also noted (Gallos et al., 2012). These findings 
underscore the importance of identifying basic mechanisms by which metabolism and O-
GlcNAcylation influence the progression of endometrial cancer, with the goal of improving 
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fertility-sparing treatments.  Therefore, the objective of this study was to determine these 
mechanisms, specifically focusing on the manipulation of O-GlcNAc cycling enzymes (OGT and 
OGA) and the impact on molecular and cellular aspects of Epithelial-Mesenchymal Transition 
(EMT).  
Materials and Methods 
Cell Culture/Reagents. Endometrial Cancer cells (Ishikawa) were obtained from Sigma Aldrich 
(cat. #99040201). Cell Line authentication was performed before, during, and after 
experimentation in the University of Vermont Cancer Center Advanced Genome Technologies 
Core and was supported by the University of Vermont Cancer Center, Lake Champlain Cancer 
Research Organization, and the University of Vermont College of Medicine. O-GlcNAcylation 
in cells was manipulated by the OGA inhibitor, ThmG (1μM, Fisher Scientific), the OGT 
inhibitor, OSMI-1 (50μM, Aobious), and supplementation of excess glucose (25Mm). ThmG and 
OSMI-1 were dissolved in DMSO (Fisher Scientific) at a concentration of 1000X, thus control 
and glucose treated cells received 0.1% DMSO (vehicle). Cell culture media (EMEM, 10% FBS 
and 10μl/mL antibiotic-anti-mycotic (Fisher Scientific) was exchanged every 24 hours unless 
otherwise specified.  
Immunoblotting. Cell Lysates were harvested via trypsin digestion and dissolved in RIPA 
buffer, and then passaged 5 times through a 26G needle. Protein concentration was measured by 
BCA Assay (BioRad) following the manufacturer’s protocol. Pre-stained SDS-PAGE gels were 
loaded with 20μg of proteins per lane. Protein was then transferred to PVDF membrane 
(Millipore). Membranes were then probed with antibodies associated with EMT (EMT antibody 
kit), the Akt Pathway (Akt Pathway Antibody Kit), O-GlcNAc (CTD 110.6), OGT, and OGA. 
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Goat-anti-rabbit and goat-anti-mouse HRP conjugated secondary antibodies were used in 
combination with Clarity Western ECL Clotting Substrate (BioRad) for imaging on the BioRad 
ChemiDoc Imager. All antibodies were purchased from Cell Signaling unless otherwise 
specified.  
Immunohistochemistry. Cells were seeded at 50,000 cells/mL in black-walled 96 wells plates 
and incubated in treatments described above, with or without 5ng/mL TGF-β (R&D Systems), 
for 72 hours. Media was exchanged daily. Cells were then fixed with 4% paraformaldehyde in 
PBS (Fisher Scientific) and stained with Alexaflour-488 Phalloidin (Molecular Probes, Eugene, 
OR) and DAPI (Molecular Probes). Cells were imaged with the Olympus CKX53 at 200X. 
Proliferation and Migration. A wound-healing assay was used to measure cell proliferation of 
Control cells (vehicle, DMSO), Hyper-O-GlcNAcylated cells (25Mm Glucose or 1μM ThmG), 
and Hypo-O-GlcNAcylated cells (50μM OSMI-1). Confluent monolayers of treated cells grown 
in 24 well plates in EMEM with 10% FBS. “Wounds” were created by running a 200μL pipette 
tip across the monolayer. At 0 hours and every 24 hours following, the “wound” area was 
measured with ImageJ software and percent wound closure was calculated. Three independent 
wound-healing assays were also conducted to assess the migration potential of treated cells. 
Confluent monolayers of treated cells grown in 24 well plates were serum starved for 24 hours 
before “wounds” were created by running a 200μL pipette tip across the monolayer. Cells were 
maintained in serum free conditions to inhibit proliferation and were incubated at 37°C and 5% 
CO2 for 18 hours. The “wound” area was measured with ImageJ software at 0 and 18 hours to 
calculate percent wound closure.  
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Invasion. Corning Matrigel Biocoat Invasion Chambers (24 well, 0.8μ) (Corning, Bedford, MA) 
were used to assess the invasion potential of treated cells compared to control. The upper 
chamber was seeded with 100,000 serum-starved cells stimulated with 5ng/ml TGF-β. Cells were 
exposed to O-GlcNAc-modifying treatments at the time of seeding. The lower chamber 
contained 5% FBS as a chemoattractant. Cells were incubated for 48 hours at 37°C and 5% CO2. 
Cells were then removed from the upper chamber and the Transwell membranes were fixed with 
100% methanol and stained with Crystal Violet. Invaded cells were then counted by two 
independent researchers and the results were averaged.  
RT PCR Array. RNA was extracted from treated cell pellets with the RNeasy Mini-Kit 
(Qiagen) with DNase digestion (RNAse free DNase Kit, QIAGEN) following the manufacturer 
protocols. The cDNA synthesis and RT2 Profiler PCR Arrays (QIAGEN, PAHS-090Z) (Supp. 
Table 1) were performed in the University of Vermont Cancer Center Advanced Genome 
Technologies Core and was supported by the University of Vermont Cancer Center, Lake 
Champlain Cancer Research Organization, and the University of Vermont College of Medicine. 
Results were analyzed via the GeneGlobe Data Analysis Center (QIAGEN).  
Oncogenomic Data Analysis. Multidimensional cancer genomic data analysis was performed 
using online data-mining tool from the cBioPortal for Cancer Genomics (http://cbioportal.org) 
and the data sets from the cBioPortal for Cancer Genomics and the TCGA research Network 
(http://cancergenome.nih.gov) according to recently published protocols.26, 27 Tumor types and 
data sets are chosen in accordance with the publication guidelines from TCGA (last update:30 
September 2014). Genomic alterations were identified when the following occurred: (1) gene 
mutations; (2) putative copy number alteration (amplification or deletion); (3) RNA expression 
54 
 
Z-scores (RNA Seq Version 2 RSEM) with Z-score thresholds±2.0; and (4) protein/phospho-
protein level (RPPA) with Z-score thresholds±2.0. 
Data Analysis. A minimum of 3 independent replicates were completed for each experiment, 
reported as mean +/- SEMs. Statistical analysis was conducted using 2-Way ANOVA and 
Student’s t-tests with JMP Pro 13 Statistical Analysis Software. Fold-change differences in 
mRNA expression were calculated with the GeneGlobe Data Analysis Center (QIAGEN) for 
RT2 Profiler PCR Arrays. 
Results 
The O-GlcNAc cycling enzymes, OGT and OGA, are altered in endometrial cancer 
Analysis of gene alterations for OGT and OGA (OGT and MGEA5, respectively) using 
data from the RNAseq and Microarray databases available in cBioPortal (cBioPortal.org) 
revealed that of the 18 female reproductive cancer databases available, Uterine/Endometrial 
Cancer ranks highest for gene alterations to OGT and MGEA5 , including both mutational and 
amplification modifications (Figure 1A). Additionally, both genes are upregulated in participants 
with Diabetes Mellitus compared to non-Diabetic controls (Figures 1B).  These findings are 
consistent with the previous assertion that O-GlcNAc enzyme gene expression is increased along 
the myometrial invasive edge of endometrial tumors (Krześlak et al., 2012). Similarly, elevated 
expression of OGT and MGEA5 mRNA is consistent with the nutrient-sensing nature of O-
GlcNAcylation.  High nutrient intake, hyperglycemia, and other metabolic abnormalities all 
promote the flow of glucose into the HBP, resulting in elevated O-GlcNAcylation. In this way, 
the current findings of the meta-analysis add support to the concept that O-GlcNAc modification 
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has a role in the development of diabetic complications and cancer (Copeland, Han, & Hart, 
2013; T Issad et al., 2010; Ruan et al., 2013).  
Detection and manipulation of O-GlcNAcylation in the endometrial cancer line, Ishikawa 
Immunodetection of global O-GlcNAcylation in Ishikawa cells revealed this form of 
protein modification was upregulated (Hyper-O-GlcNAcylation) in cells by supplementing 
complete media with 25mM Glucose or by inhibiting OGA with Thiamet-G (1μM; ThmG) 
(Figures 1C and 1D), and downregulated (Hypo-GlcNAcylation) by inhibiting OGT with OSMI-
1 (50μM) (Figures 1C and 1 D).  These manipulations of O-GlcNAcylation were then utilized in 
all subsequent experiments to determine effects of aberrant O-GlcNAcylation on phenotypic 
changes in Ishikawa cells (i.e., cell proliferation/migration and invasion), as well as 
morphological and molecular alterations associated with EMT.  
Hyper-O-GlcNAcylation supports endometrial cancer cell proliferation/migration, and 
promotes invasion  
A wound healing assay demonstrated that Hyper-O-GlcNAcylation supported Ishikawa 
cell proliferation and migration, with no difference in wound closure observed among Control, 
Glucose and ThmG-treated cultures (p>0.05; Figures 2A and B).  Hence, Hyper-O-
GlcNAcylation was conducive to wound closure.  Conversely, Hypo-O-GlcNAcylation (via 
OSMI-1) impaired cell proliferation/migration (p<0.05), resulting in wounds that failed to close 
within the time constraints of the experimental period (~40% wound closure after 72- hours of 
culture; Figures 2A and B). The inhibition was serum-dependent, however, as no difference in 
wound closure was observed among the treatment groups when FBS was excluded from the 
culture medium (p>0.05; Figure 2C).  
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Although Ishikawa cells are considered relatively-low metastatic cells (Kaori Ohtani, 
Hideki Sakamoto, Thomas Rutherford, Zhaocong Chen, Kazuo Satoh, 1999), treatment with 
Hyper-O-GlcNAcylation (ThmG treatment) augmented invasiveness compared to Control and 
Hypo-O-GlcNAcylated (OSMI-1-treated) cells (p<0.05; Figures 2D and E).   Glucose 
supplementation provided an intermediate response, midway between Control and Hyper-O-
GlcNAcylated cells (Figure 2E). The Hypo-O-GlcNAcylated cells (OSMI-1-treated) exhibited 
no invasion potential, comparable to Controls (p>0.05; Figures 2D and E). 
Hyper-O-GlcNAcylation promotes the EMT phenotype 
The EMT process was examined in Ishikawa cells at both the mRNA and protein levels by 
manipulating O-GlcNAc modification (as previously described). Phalloidin staining of stress 
filaments in these cells (F-actin) revealed diffuse and epithelial-like staining in Hypo-O-
GlcNAcylated (OSMI-1- treated) cells (Figure 3A).  Conversely, Hyper-O-GlcNAcylation 
(Glucose and ThmG-treatment) of cells resulted in conspicuous F-actin staining throughout the 
cytoplasm and stress fiber-like bundles along the marginal borders of the cells (white arrows, 
Figure 3A), indicative of mesenchymal cell morphology. 
Despite the observed morphological changes in Hypo- and Hyper-O-GlcNAcylated cells, 
there was no evidence of changes in transcript abundance for key EMT markers (ZEB1, CDH1, 
CDH2, CTNNB1, VIM, SNAI1, SNAI2, and CLDN1) among the treatment groups as assessed by 
qPCR analysis (Table 2). Similarly, immunoblots indicated no change in E-Cadherin (CDH1) 
expression compared to Control cells; (Figures 3B and 3C). Although, expression of the E-
Cadherin suppressor, Snail, was supported by all treatments, Hyper-O-GlcNAcylation via ThmG 
increased Snail expression to a greater extent than that of high glucose (p<0.05; ThmG vs. 
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Glucose, respectively, Figure 3C). The expression of β-Catenin was down-regulated by Hypo-O-
GlcNAcylation (OSMI-1), while Hyper-O-GlcNAcylation (ThmG) sustained β-Catenin 
expression (p<0.05; Figure 3C). Claudin-1, a major constituent of tight junction complexes, was 
noticeably decreased by Hyper-O-GlcNAcylation (ThmG) and Hypo-O-GlcNAcylation (OSMI-
1) compared to Control cells (p<0.05; Figure 3B).  None of the other detected EMT markers (N-
Cadherin, ZO-1, Vimentin, Slug, ZEB1) were affected by O-GlcNAcylation status (p>0.05; 
Figure 3B). 
 Microarray analysis corroborates dysregulation of O-GlcNAcylation as a mechanism of 
EMT in endometrial cancer 
The above-described phenotypic changes were supported by mRNA analysis of 86 genes 
important to the process of EMT. The EMT RT2 Profiler PCR Array and GeneGlobe Data 
Analysis Center analysis tool (Qiagen), was used to measure changes in gene expression (2 fold 
or greater) compared to Control cells (Supp. Table 2). Three independent experiments yielded 
the same mRNA expression profile for both Hyper-O-GlcNAcylation treatments, with increased 
expression of FOXC2 and WNT5B, both promoters of EMT, and KRT14, a cytoskeletal 
intermediate filament monomer (Figure 4). Hypo-O-GlcNAcylated cells also had increased 
WNT5B and KRT14, however, Hypo-O-GlcNAcylation decreased the expression of AHNAK, 
CALD1, FGFBP1, TGFB2, TFPI2 genes (Figure 4).  The AHNAK, CALD1, and TGFB2 genes 
are all typically up-regulated during EMT, while FGFBP1 and TFPI2 are commonly 





 Figure 1. 
Figure 1: Meta-analysis of O-GlcNAc alteration in female cancers and Validation of global O-
GlcNAc modification in Ishikawa cells.  Cancer genomics data analysis depicting a cross-cancer 
O-GlcNAc enzyme (OGT, MGEA5) alteration summary of female cancers. [A] Histograms 
depicting the level of gene amplification, mutation, or deletion in each data set. Data was mined 
from the TCGA database and was analyzed with the cBioPortal web analysis tool. Of these 18 
female cancer datasets, uterine/endometrial cancer ranked the highest for gene alterations of OGT 
and MGEA5. [B] Box plots comparing the relative mRNA expression of OGT and MGEA5 in 
patients with or without a diagnosis of diabetes mellitus (DM). Additional analysis of the data set 
revealed that OGT and MGEA5 mRNA was more highly expressed in endometrial cancer patients 
with DM. [C] Western Blot analysis of global O-GlcNAc modification, relative to total protein, in 
whole cell Ishikawa lysates treated with the OGT inhibitor, OSMI-1, the OGA inhibitor, Thiamet-G, 
or supplemented with 25mM Glucose. Both Glucose and Thiamet-G increased O-GlcNAcylation; no 
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 Figure 4. 
Figure 4. Disruption of O-GlcNAc alters gene expression in EMT related genes in Ishikawa 
cells. Cells were cultured with OSMI-1, Thiamet-G, 25mM glucose, or vehicle for 48 hours before 
being harvested for RNA isolation. The mRNA was the quantified by RT-PCR (n=3) and depicted is 
relative expression of cells grown in [A] 25mM glucose, [B] Thiamet-G, and [C] OSMI-1 compared 
to vehicle (control). The lines encompass 2-fold changes. Genes up-regulated are denoted by red 
circles, whereas genes down-regulated appear as green circles.  Black circles constitute genes that 
were relatively unchanged. [D] The chart and heatmap summarize the results compared to anticipated 













O-GlcNAcylation is a recently discovered post-translational modification of cellular 
proteins that is highly abundant and ubiquitous throughout the nuclear and cytoplasmic 
compartments of the cell, yet its influence on cellular processes is poorly understood. First-
discovered about 30 years ago (Torres & Hart, 1984),  O-GlcNAc is an end-product of the 
hexosamine biosynthesis pathway (HBP), where its relative concentration serves as nutrient 
sensor indicative of metabolic status(Palin et al., 2014). Indeed, elevated O-GlcNAcylation (i.e., 
Hyper- O-GlcNAcylation), for example, is a hallmark of high metabolism seen in many types of 
cancers (Singh et al., 2015), including cancers of the breast (S a Caldwell et al., 2010), 
liver(GUO et al., 2012), bladder (Rozanski et al., 2012), prostate (Itkonen et al., 2013), lung(Mi 
et al., 2011), colon (Kamigaito et al., 2013; Mi et al., 2011), and endometrium(Krześlak et al., 
2012). Thus, O-GlcNAc, and by extension O-GlcNAcylation, may constitute an important 
regulator of cancer development and progression, while simultaneously providing a potential, 
novel connection between the onset of T2D and the increased risk of certain cancers (Gallagher 
& LeRoith, 2015).  Endometrial cancers fall into this category of increased risk attributable to 
T2D (Byrne et al., 2014; Friberg et al., 2007; Zelenko & Gallagher, 2014), and the current study 
is the first, to our knowledge, to reveal that aberrant O-GlcNAcylation mechanistically-augments 
tumorigenicity of endometrial cancer cells. 
One mechanism responsible for increased tumorigenicity in many cancers is the 
phenomenon of epithelial-mesenchymal transition (EMT). Although most scientists 
acknowledge that EMT is a critical process of embryogenesis, this same process enhances tumor 
development and metastasis (Kondaveeti, Guttilla Reed, & White, 2015; Tam & Weinberg, 
2013; Yilmaz & Christofori, 2009).  Some of the key characteristics of EMT include the loss of 
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cell polarity and cell-cell adhesions, and an increase in invasive properties (Larue & Bellacosa, 
2005; Rojas-Puentes et al., 2016). In the current study, Hyper-O-GlcNAcylation supported cell 
proliferation, induced reorganization of the cytoskeleton, and promoted invasion of endometrial 
cancer (Ishikawa) cells.   
Intercellular adhesion, mediated largely by cadherin and catenin proteins, is a critical 
obstacle for epithelial cells to overcome as they de-differentiate and become more tumorigenic.  
A decrease in E-Cadherin expression, for instance, is among the initiating steps of EMT (Onder 
et al., 2008; Yao, Dai, & Peng, 2011), and is a notable consequence of Hyper-O-GlcNAcylation 
in many cell types (Fardini et al., 2013). Snail1, an E-Cadherin suppressor, is stabilized by O-
GlcNAc at Ser112 under hyperglycemic culture conditions (Sang Yoon Park et al., 2010), and O-
GlcNAcylation of E-Cadherin can occur directly via the cytoplasmic domain, which 
consequently inhibits its transport to the cell surface and prevents intercellular adhesion(Zhu et 
al., 2012). In the current study, Hyper-O-GlcNAcylation increased the expression of Snail1, but 
the effect was modest and had no overall impact on E-Cadherin expression or the expression of 
any other EMT protein markers.   This suggests that the alteration of E-Cadherin expression is 
perhaps less critical for EMT in Ishikawa cells, or that the period of time required for this type of 
transition is much longer than that evaluated in the current experiments (48 hrs). 
A major group of cellular signaling pathways associated with EMT are the Wnt signaling 
pathways. Of the Wnt pathways, 3 have been characterized; the canonical pathway, the 
noncanonical pathway, and the noncanonical Wnt/Calcium pathway (Yilmaz & Christofori, 
2009). In the canonical pathway, Wnt induces the expression of the mesenchymal-like protein, 
Beta-catenin. Beta-catenin accumulates in the cytoplasm and is translocated to the nucleus, 
where it acts as a transcriptional activator of TCF/LEF family transcription factors, which in turn 
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induces a cellular response (Polakis, 2000). A recent study investigating the role of high glucose 
concentrations in endometrial cancer found that high glucose increased the flux of glucose into 
the HBP, in turn increasing O-GlcNAcylation of proteins (Zhou et al., 2016). Hyper-O-
GlcNAcylation also increased the expression of B-catenin (Zhou et al., 2016). In contrast, an 
upregulation of the non-canonical Wnt ligand, WNT5B, by any form of O-GlcNAc dysregulation 
(i.e., Hyper- and Hypo-O-GlcNAcylation), occurred in the current study, and this outcome did 
not affect the canonical Wnt ligands (i.e. Wnts -1, -2, -3, -8a, -8b, -10a, -10b)(Siar et al., 2012) or 
β-catenin expression (Figures 4 and 3B, respectively). The non-canonical Wnt pathways are not 
as well understood as the canonical, partly due to the diversity and sheer number of pathways. 
However, one such intracellular pathway activated by Wnt5b is the Planar Cell Polarity (PCP) 
pathway, which controls tissue polarity and cell migration (Spandidos & Ethnikon Hidryma 
Ereunōn, 1994). WNT5B is up-regulated in MCF-7 cells(Panepistēmio tēs Krētēs. & Katoh, 
2002) and is associated with cell migration and proliferation in lung cancer cells (Harada et al., 
2016).  In preadipocytes, WNT5B overexpression partially inhibits canonical Wnt/β-catenin 
signaling, thereby promoting adipogenesis (Kanazawa et al., 2005). In addition to its role in 
cancer and metastasis, non-canonical Wnt signaling also promotes metabolic dysfunction and 
adipose tissue inflammation, which is critical to the development of insulin resistance (Fuster et 
al., 2015). Collectively, these observations lead us to suggest that, in Ishikawa cells, 
dysregulation of O-GlcNAc signaling promotes EMT through activation of non-canonical Wnt 
signaling by WNT5B overexpression, which may in turn inhibit Wnt/β-catenin signaling. Such a 
mechanism might also help explain the connection between insulin resistance and increased risk 
of endometrial cancer.  
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In addition to increased WNT5B expression, the transcription factor, Forkhead box 
protein C2 (FOXC2) is highly-expressed in Hyper-O-GlcNAcylated Ishikawa cells. In 
accordance with these results, there is often increased expression of FOXC2 during EMT, and 
over-expression of FOXC2 is associated with highly-metastatic cancers (Hollier et al., 2013), 
some of which can be reduced  by shRNA therapy (Paranjape et al., 2016). In podocytes, for 
instance, increased FOXC2 is associated with increased vimentin expression, cytoskeletal 
reorganization, disruption to ZO-1 localization, and increased cell motility (Datta, Lindfors, 
Miura, Saleem, & Lehtonen, 2016). Thus, there is support for the concept that Hyper-O-
GlcNAcylation of Ishikawa cells induces EMT and metastasis via a FOXC2-mediated 
mechanism. 
Cytoskeletal re-organization is key feature of EMT. Cytokeratin intermediate filaments 
are often considered biomarkers of cancers, but are more frequently gaining attention as 
mediators of disease (Karantza, 2011; Pan et al., 2013).  Perhaps the best example of this is 
Keratin 18, a component of cytokeratin 8/18 intermediate filaments, which has long been used as 
a marker for apoptosis in cancers (Lomnytska & Souchelnytsky, 2007), but the loss of keratin 18 
expression in cells is associated with EMT (Fortier et al., 2013a).  In our previous work utilizing 
cervical cancer cells, we determined  that Hypo-O-GlcNAcylation reduces and re-organizes 
cytokeratin 8/18 filaments, which suggests that O-GlcNAcylation influences filament expression 
and stability (Jaskiewicz, et al, 2017). Similar results were noted in the current study, as both 
Hyper- and Hypo-O-GlcNAcylation increased the expression of Keratin 14 mRNA in 
endometrial cells. Others have shown that co-expression of vimentin and keratin in MCF-7 
breast cancer cells increases cell invasiveness (Hendrix, Seftor, Seftor, & Trevort, 1997). Hyper-
O-GlcNAcylation in Ishikawa cells in the current study increased Keratin 14 expression, had no 
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effect on vimentin expression, and yet increased metastatic potential. These findings are 
intriguing and warrant further investigation into the potential regulation of keratin filaments by 
O-GlcNAcylation, and a possible role in disease progression.  
In summary, dysregulation of O-GlcNAcylation supports EMT and cytoskeletal re-
organization in endometrial cancer cells, potentially through activation of the noncanonical Wnt 
signaling pathway by WNT5B. Additionally, Hyper-O-GlcNAcylation induces the expression of 
FOXC2 and augments the invasion potential of the cells. These findings indicate Hyper-O-
GlcNAcylation, such as that observed in diabetic individuals (Medford et al., 2012), could 
enhance the aggressiveness of endometrial cancer. Conversely, Hypo-O-GlcNAcylation impaired 
endometrial cancer cell proliferation and wound healing, and down-regulated expression of pro-
EMT genes (AHNAK, CALD1, and TGFB2).  These observations suggest that metabolic status, 
particularly as it relates to O-GlcNAcylation, might be an important consideration in therapeutic 
approaches to endometrial cancer. Future studies should focus on aberrant O-GlcNAcylation as a 
potential marker for more aggressive disease in human tissues, and the inhibition of Hyper-O-
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HYPER-O-GLCNACYLATION IMPAIRS THE ANTI-PROLIFERATIVE AND ANTI-
INVASIVE PROPERTIES OF PROGESTERONE IN ENDOMETRIAL CANCER CELLS 
 
Introduction 
Hyper-O-GlcNAcylation of proteins is a subsequent artifact of metabolic disorder 
(Keembiyehetty et al., 2015) and is indicative of many cancers (Ma & Vosseller, 2013; Onodera, 
Nam, & Bissell, 2014), including endometrial cancer (Krześlak, Wójcik-Krowiranda, Forma, 
Bieńkiewicz, & Bryś, 2012). While the incidence of most types of cancer has declined in the 
U.S., endometrial cancer remains on the rise, disproportionately affecting black women (Cote, 
Ruterbusch, Olson, Lu, & Ali-Fehmi, 2015). The mean age for onset of endometrial cancer is 60 
years, but at least 14% of cases diagnosed are women of reproductive age (Evans-Metcalf, 
Brooks, Reale, & Baker, 1998). These women have the option to postpone surgical treatment in 
favor of fertility-sparing progestin therapy (Jeong-Yeol Park, 2015; Kesterson & Fanning, 2012; 
Ramondetta, Burke, Broaddus, & Jhingran, 2006), but there are inevitable risks associated with 
this alternative, including the risk for undiagnosed synchronous or metastatic cancer. In a meta-
analysis of 27 studies, 76% of  the women responded favorably to progestin treatment, however, 
24% of these patients had recurring disease within 19 months post treatment (Ramirez, 
Frumovitz, Bodurka, Sun, & Levenback, 2004). Additionally, many endometrial cancer patients 
are obese and/or suffer from metabolic disorders like insulin resistance and hyper-glycemia 
(Byrne et al., 2014), which results in global hyper-O-GlcNAcylation (Trinca & Hagan, 2017) 
and can confound therapeutic approaches.  
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Progesterone (P4) therapy reduces cell growth and invasion in endometrial cancer 
through the up-regulation of the cyclin dependent kinase inhibitors, p21 and p27 (Dai, Wolf, 
Litman, White, & Leslie, 2002; Shimizu et al., 2009); mechanisms that can also be influenced by 
O-GlcNAcylation. The tumor suppressor, p27 is highly O-GlcNAcylated, and an O-GlcNAc 
modification at Ser2 promotes the accumulation of p27 in the cytoplasm of HEK293 and 
hepatocellular carcinoma (HCC) cell lines (Qiu et al., 2017). Furthermore, the PI3K/Akt pathway 
is heavily influenced by O-GlcNAcylation (Gandy, Rountree, & Bijur, 2006; Jóźwiak, Forma, 
Bryś, & Krześlak, 2014), and can regulate the expression of both p21 (Lawlor & Rotwein, 2000; 
Rössig et al., 2001) and p27 (Graff et al., 2000) to further augment human cancers (Vivanco & 
Sawyers, 2002).  
In the current study, the objective was to investigate the influence of hyper-O-
GlcNAcylation on the efficacy of progestin therapy in endometrial cancer cells.  Ishikawa cells 
(an immortal endometrial cancer cell line) were exposed to the O-GlcNAcase inhibitor, Thiamet-
G (ThmG), to induce hyper-O-GlcNAcylation and then test the efficacy of a therapeutic 
concentration of P4 (100nM) to inhibit Ishikawa cell proliferation and invasion. 
Materials and Methods 
Cell Culture and Reagents. Endometrial cancer cells (Ishikawa) were obtained from Sigma 
Aldrich (cat. #99040201). Cell Line authentication was performed before, during, and after 
experimentation at the University of Vermont Cancer Center Advanced Genome Technologies 
Core and was supported by the University of Vermont Cancer Center, Lake Champlain Cancer 
Research Organization, and the University of Vermont College of Medicine. O-GlcNAcylation 
within the cells was manipulated by the OGA inhibitor, ThmG (1μM, Fisher Scientific) 
dissolved in DMSO (Fisher Scientific) at a concentration of 1000X.  Control cells received an 
72 
 
equivalent concentration (0.1%) of DMSO as vehicle. Progesterone was administered to cells at 
100nM as reported by others (Dai et al., 2002), and dissolved in ethanol (0.1%). Cell culture 
media (EMEM, 10% FBS and 10μl/mL antibiotic-anti-mycotic) (Fisher Scientific) was 
supplemented with 10nM estradiol (E2, #E1132, Sigma,; a gift from Dr. Catherine Combelles, 
Middlebury College) to support progesterone receptor expression as described (Holinka, Hata, 
Kuramoto, & Gurpide, 1986). Culture medium was exchanged every 24 hours unless otherwise 
specified.  
Immunoblotting. Whole cell lysates of Ishikawa cells cultured in 25cm2 flasks (Corning, 
Corning, NY) for 48 hours, were harvested by trypsin and lysed with RIPA buffer and passage 
through a 26G needle. Proteins were then separated on pre-stained SDS-Page gels (BioRad, 
Hercules, CA) and transferred to PVDF membrane. Membranes were then probed for global O-
GlcNAcylation (CST-O-GlcNAc 110.6 antibody; Cell Signaling Technology, Inc.; Beverly, 
MA), p21 (p21 Waf1/Cip1 (12D1) Rabbit mAb #2947, Cell Signaling), and p27 (p27 Kip1 
(D69C12) XP® Rabbit mAb #3686, Cell Signaling) proteins.  Detection was achieved using 
secondary antibody (Anti-rabbit IgG HRP-linked Antibody, Cell Signaling Technology, Inc.), 
followed by Clarity Western ECL substrate (BioRad). Blots were imaged on the BioRad 
ChemiDoc Imaging System, and densitometry was calculated with Image J. 
Cell Proliferation Assay. In a set of 3 independent experiments, cells were seeded in duplicate 
in flat-sided Thermo Fisher Scientific™ Nunc™ Cell Culture Tubes at an initial seeding density 
of 50k cells/ml of culture medium. Treatment groups included cultures of cells continuously 
exposed to vehicle (DMSO-Control), 1 μM Thiamet-G, and 100nM P4 accordingly. The 
conditioned culture medium was exchanged without/with treatment daily, and the cells for each 
group were harvested for counting at 24-hour intervals over a three-day period.  
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Matrigel Invasion Assay. Corning Matrigel Biocoat Invasion Chambers (24 well, 0.8μ) 
(Corning, Bedford, MA) were used to assess the invasion potential of treated cells compared to 
control. The upper chamber was seeded with 100,000 serum-starved cells. Cells were exposed to 
O-GlcNAc-modifying treatments and progesterone at the time of seeding. The lower chamber 
contained 5% FBS as a chemoattractant. Cells were incubated for 48 hours at 37°C and 5% CO2. 
Cells were then removed from the upper chamber and the Transwell membranes were fixed with 
100% methanol and stained with Crystal Violet. Invaded cells were then counted by two 
independent researchers and the results were averaged.  
Results 
Proliferation and Invasion. 
A three-day cell proliferation assay confirmed the anti-proliferative effects of 100nM 
progesterone reported in the literature (Dai et al., 2002), (p<0.05 P4 treatment extended the 
doubling time by 21%; however, simultaneous treatment with ThmG negated this effect and 
resulted in a doubling time comparable to control (19.50 +/- 0.48 hours vs. 19.52 +/- 0.35 hours, 
respectively; Figure 1). In contrast, P4 did not decrease the invasion potential of Ishikawa cells 
compared to control, however ThmG treatment with or without progesterone did increase the 
invasiveness compared to progesterone treatment alone, (p<0.05, Figure 2).  
Inhibition of OGA augments O-GlcNAcylation in Ishikawa cells; an effect impaired 
by P4 and downregulation of OGT expression. 
 OGA inhibition by Thiamet-G increased O-GlcNAcylation by 3-fold compared to 
control cells. Interestingly, and reduced OGT expression as reported in the literature. 
Progesterone treatment reduced the expression of OGT compared to control, and this was further 
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reduced by ThmG and P4 in combination. Subsequently, the level of O-GlcNAc modification 
was also reduced compared to cells treated with ThmG alone (p<0.05, Figure 3). 
Inhibition of OGA by ThmG, reduces PR A and B and p27 expression in Ishikawa cells. 
Progesterone treatment maintained PR A and PR B expression while, hyper-O-
GlcNAcylation, induced by ThmG treatment, reduced both PR A and PR B expression (p<0.05), 
even with progesterone treatment (p<0.05). Progesterone reduced p21 expression compared to 
control cells (p<0.05, Figure 3). Interestingly, p21 expression was increased compared to control 
cells in hyper-O-GlcNAcylated cells (ThmG) that were also treated with P4 (p<0.05, Figure 3). 
Progesterone treatment maintained control levels of p27, but hyper-O-GlcNAcylation reduced 
p27 expression compared to control cells, regardless of P4 treatment. However, p27 expression 
was increased compared to ThmG treatment alone when P4 was added to the culture media 















































Control Control P4 ThiametG ThiametG P4
 Doubling Time (Hours) +/- SEM 
Control (DMSO, etOH) 19.52 0.35 
P4 (100nM) 23.73 * 0.63 
Thiamet-G (1μM) 19.94 0.069 
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24 Hours   48 Hours   72 Hours C. 
Figure 1. [A] Growth curve depicting the average (n=3) daily total cell counts for cells 
grown in control conditions (vehicle, DMSO and etOH), 100nM P4, 1μM ThmG, or a 
combination of ThmG and P4. [B] Doubling time +/-SEM calculated from growth curve 
data. [C] Representative images (n=3) of cell culture confluency at 24, 48, and 72 hours 
imaged at 20X magnification. * Specifies statistical significance (p<0.05). 
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Figure 2. [A] Representative images of Transwell invasion assay membranes (n=4), fixed 
invasive cells stained with Crystal Violet (20X). [B] Bar graph denoting average (n=4) 
percent invasive population counted by 2 independent researchers. Different letters denote 
significant statistical differences (p<0.05). 














Figure 3. [A] Representative images of 
western blot analysis (n=3) of whole cell 
Ishikawa lysates probed for O-GlcNAc, 
endogenous Progesterone Receptor A and 
B, p21, p27, and OGT. [B] Densitometry 
analysis of Western Blots relative to total 
protein, bars represent the mean +/- SEM 
(n=3), different letters denote statistically 























Hyper-O-GlcNAcylation overcomes the inhibitory effects of progesterone therapy on cell 
proliferation and invasion in Ishikawa cells.  
Hyper-O-GlcNAcylation, particularly by the inhibition of OGA, increases cell 
proliferation in many cell types (Fardini, Dehennaut, Lefebvre, & Issad, 2013). This includes our 
own previous work in Ishikawa cells, discussed in Chapter 4. In the current study, OGA 
inhibition by ThmG, increased O-GlcNAcylation and supported both proliferation and invasion 
despite the therapeutic (i.e., inhibitory) effect of P4 treatment. Unlike previous studies (Dai, 
Wolf, Litman, White, & Leslie, 2002; Shimizu et al., 2009), however, P4 in the current work had 
no impact on cell invasion.  This result is attributed to likelihood that OGA inhibition (via 
ThmG) promoted cell invasion through mechanisms associated with Epithelial-to-Mesenchymal 
Transition (EMT) as discussed in Chapter 4. In previous studies also conducted in Ishikawa cells, 
P4 was found to reduce EMT in vitro, however loss of PR expression correlated with increased 
EMT and more progressive disease (Van der Horst, et al., 2012). 
Progesterone impairs OGT expression and subsequent O-GlcNAcylation 
To our knowledge, the current study is the first to provide evidence that P4 impairs global 
O-GlcNAcylation in endometrial cancer cells and this effect is associated with the reduction of 
expression of O-GlcNAc cycling enzymes, namely OGT. P4 reduced the expression of OGT 
both alone and in combination with the OGA inhibitor, ThmG. While the mechanism for this 
effect is unclear, P4 does influence carbohydrate metabolism by inducing hyperinsulinemia and 
promoting glycogen storage in the liver  (Kalkhoff, 1982).  In this manner, P4 could regulate the 
amount of glucose shuttled to the Hexosamine Biosynthesis Pathway. A reduction of OGT 
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expression is associated with reduced proliferation, adhesion, and migration  of cells in a fetal 
human cancer cell line (Steenackers et al., 2016). Thus, it is conceivable that the anti-
proliferative and anti-invasive effects of P4 are attributable to a reduction in OGT.  
Progesterone Receptor expression is influenced by Progesterone and O-GlcNAcylation 
Ishikawa cells expressed Progesterone Receptors A and B in all treatment types, 
however, ThmG significantly reduced both PR A and PR B regardless of progesterone treatment. 
A study conducted in 2003 established two stable Ishikawa cell lines, hPR A and hPR B 
expressing cells, to study the individual effects of PR A and B receptors. Only the cells that 
expressed PR B alone were growth responsive to progesterone treatment, while the PR A 
expressing cells continued to proliferate (Smid-Koopman et al., n.d.). In breast cancer, PR A 
tends to be predominantly expressed, leading to reduced progestin responsiveness (Graham et al., 
2005). In congruency with these observation, cell treated with ThmG exhibited reduced PR A 
and PR B expression and continued to proliferate normally despite P4 treatment. This suggests 
that the downregulation of PR by OGA inhibition and subsequent hyper-O-GlcNAcylation could 
protect endometrial cancer cells from the effects of progestin treatment, and possibly even 
promote growth.  
P27 expression can be regulated by both P4 and Hyper-O-GlcNAcylation 
The cyclin dependent kinase inhibitor, p27, is generally described as a tumor suppressor. 
In this study, P4 treatment maintained the expression of p27 compared to control cells, however 
in similar cell lines P4 promoted the expression of p27 (Dai et al., 2002). Alternatively, treatment 
with the OGA inhibitor, ThmG, reduced the expression of p27. Decreased expression of p27 has 
been related to poor prognosis in lung, esophageal, colon, breast, and prostate cancers, of which 
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O-GlcNAcylation is also largely elevated (Abukhdeir & Park, 2008). When cells were treated 
with P4 and ThmG in combination, p27 expression did increase, but did not return to control 
levels (Figure 3).  
In this instance, Hyper-O-GlcNAcylation did reduce the anti-proliferative effect of P4 
through the reduction of p27 expression, which translated to an increase in cell proliferation 
(Figure 1) despite P4 treatment. The tumor suppressor p27 is heavily O-GlcNAcylated (Ser2, 
Ser106, Ser110, Thr157, and Thr198) in HEK293 cells and hepatocellular carcinoma (HCC) 
cells. In these cells, O-GlcNAcylation and phosphorylation of p27 were found to have a dynamic 
interplay. O-GlcNAcylation at Ser2 promoted the nuclear export of p27 and increased 
phosphorylation of p27, both resulting in the accumulation of p27 in the cytoplasm, supporting 
cell cycle progression (Qiu et al., 2017). Furthermore, increased Akt activity also contributes to 
increased cell growth through a reduction p27 expression in prostate cancer (Graff et al., 2000), 
and O-GlcNAcylation is a known activator of Akt signaling (Shi et al., 2012). Further work 
should assess the nuclear and cytoplasmic expression of p27, as well as Akt activity to further 
elucidate the mechanism by which OGA inhibition reduces p27 expression and maintains cell 
cycle progression and proliferation.  
Co-treatment with P4 and ThmG increase p21 expression in Ishikawa cells 
          In previous studies, P4 treatment had been shown to reduce cell proliferation in 
endometrial cancer cells (Hec50) partially through the up-regulation of the cyclin-dependent 
kinase inhibitors p21 and p27 (Dai et al., 2002). In contrast, similar experiments conducted in the 
endometrial cancer cell line, Ishikawa, reduced p21 expression (Figure 3). In other studies 
conducted in Ishikawa cells, p21 expression was found to be unchanged by estradiol, 
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progesterone, or hCG (Abıke et al., 2013). Despite the lack of p21 expression, the proliferation 
rate remained notably reduced in cells treated with P4 (Figure 1, p<0.05), suggesting that the 
inhibition of cell proliferation in P4 treated cells was not related to the expression of cyclin-
dependent kinase inhibitors. However, when cells were treated with both P4 and ThmG, p21 
expression was increased. A possible explanation for this is that progesterone activates the p21 
promoter through an Sp1 site. O-GlcNAcylation of Sp1 may stabilize and activate Sp1 (Ma & 
Vosseller, 2014), which could in turn promote p21 expression. The expression and function of 
p21 can be altered through phosphorylation by Akt. In endothelial cells, activated Akt 
phosphorylates p21, which results in its reduced ability to inhibit Cdk2 activity, presumably by 
inhibiting p21/cdk2 complex binding (Rössig et al., 2001). This suggests that hyper-O-
GlcNAcylation may promote the phosphorylation of p21 by Akt, thus impairing its anti-
proliferative function. 
Conclusion 
         While these results are intriguing, it’s clear that the relationship between PR and O-
GlcNAcylation is complex and warrants further study. We suggest the following experiments to 
continue this investigation: 1) quantitative cell cycle analysis 2) assessment of cell 
viability/apoptosis, and 3) further investigation into the potential relationship between O-
GlcNAcylation and progesterone and Akt signaling. Understanding the impact O-GlcNAcylation 
may have on the anti-proliferative and anti-invasive effects of progestin could have significant 
implications for the treatment of female cancers. Such knowledge could lead to improved 

































CONCLUSIONS AND FUTURE WORK 
 
            In the present work, global O-GlcNAcylation in cells was manipulated by 
pharmacological inhibition of O-GlcNAc cycling enzymes to better understand its influence on 
tumorigenic potential in female cancers. While there is significant literature exists discussing the 
role of O-GlcNAcylation in breast and ovarian cancer, very little attention has been paid to 
cervical and endometrial cancer, despite their connection to metabolic disorders. As such, this 
research project fills an important gap in our literary knowledge, making a modest yet substantial 
contribution to the fields of glycobiology and reproductive oncology. The finding that Hyper-O-
GlcNAcylation consistently supports a more tumorigenic phenotype in multiple cell lines 
confirms the importance for understanding how nutrition and metabolic health influence chronic 
disease. This topic will continue to be of great importance to human health as the obesity 
epidemic progresses (Conway et al., 2018). 
        While basic science cell culture based studies like this one are critical first steps in 
understanding molecular mechanisms of disease, they are not without limitations. We must first 
consider the cell culture model. The SiHa and Ishikawa cell lines utilized for this work are 
immortalized cell lines that have been cultured for extended periods of time. It is well known 
that as cells remain in culture, they begin to adapt to the aqueous culture conditions and behave 
very differently than cells in vivo (Kaur & Dufour, 2012). Thus it is important that these cell 
culture studies be interpreted as such. It is also important to note that no two cell lines are alike, 
and despite being the same tissue type, different cell lines can produce different results. For 
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example, the preliminary work for chapters 2 and 3 was completed with the well know cervical 
cancer cell line, HeLa. While these cells provided interesting and unique results, in surprising 
contrast to SiHa cells, it was discovered that HeLa cells had undergone such drastic mutation that 
they were no longer a reliable model of cervical cancer (Landry et al., 2013). In future studies we 
set out to use multiple cell lines to further validate our work. We originally selected Ishikawa 
and ECC-1 cells for the experiments described in Chapters 4 and 5, however, genomic validation 
of the cell lines revealed they were in fact the same cell line (Korch et al., 2012), likely a result 
of earlier contamination or misidentification. As you can see, there are many potential pitfalls 
associated with cell culture experimentation; however, it is a critical tool for the early 
development of studies that lend to progressive work with primary tissues and in vivo models.     
          Additional consideration should be given to use of pharmacological inhibitors. While they 
are a relatively simple, rapid, and cost-effective way to study the function of a protein, they are 
not without drawbacks. When working with small molecule inhibitors it is critical to be aware of 
the specificity of the inhibitor. Inhibitors that do not have a proven selectivity can have 
unintended effects on cell function, which can over shadow experimental results. An example of 
this is discussed in chapters 1 and 2, is the OGT inhibitor Alloxan, which was later discovered to 
have cytotoxic effects beyond the inhibition of OGT. Those experiments were later repeated with 
the new, more specific small molecule inhibitor, OSMI-1 (Chapter 3). A complimentary 
technique for validating data collected with a small molecule inhibitor would be the use of 
knockdown approaches such as si- or shRNA (D. D. Rao et al., 2009) which reduce the 
expression of the associated genes.  
       The difficulties presented by the nature of O-GlcNAc modification have been difficult to 
overcome, but in just over three decades the tools and techniques available to researchers have 
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grown exponentially, and they likely will continue to do so. Although our laboratory has a 
particular interest in cytoskeletal filaments, this collection of work focused on global whole-cell 
O-GlcNAcylation. While this type of broad analysis is vital for our understanding of this nutrient 
sensing modification, it is my hope that future work will progress to focus on specific proteins 
and modification sites of interest. As mentioned in chapter 1, this type of work has been done 
with the implementation of genomic point mutation techniques. With the increased availability 
of CRISPR/Cas9 gene editing technology this type of research will likely continue to expand, 
and could potentially lead minimally invasive treatments for O-GlcNAc related diseases.  
          O-GlcNAcylation’s influence on cell metabolism has made it a hot topic issue in diabetes 
and cancer research, leading to expansive literature; however, there are many areas of human and 
animal health where O-GlcNAcylation has only minimally been addressed. One such area of 
interest is mammalian reproduction. Despite a significant connection between metabolic 
syndrome and reproductive health (Al Awlaqi et al., 2016), O-GlcNAc is not currently on the 
radar of researchers. Literature on the topic is nearly non-existent, for example, a PubMed search 
produces only one publication mentioning O-GlcNAcylation in granulosa cells; “Transcriptome 
profiling of granulosa cells of bovine ovarian follicles during growth from small to large antral 
size follicles” (Hatzirodos et al., 2014). This study, published in 2014, identified the OGA 
encoding gene, MGEA5, as a regulator of small follicles, and found it to be down-regulated in 
large follicles. This suggests that O-GlcNAcylation is an important component in 
folliculogenesis; however, this concept has not been studied further.  
      Similarly, there are many aspects of male reproduction that could be influenced by O-
GlcNAcylation. For example, many of the same molecules and mechanisms critical to the EMT 
phenotype, the subject of chapter 4, are also critical in maintaining the Blood-Testes-Barrier 
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(TBT) (Mruk & Cheng, 2015). This includes, Notch signaling, PI3K, Occludins, claudins, β-
catenin, N-Cadherin, and ZO-1. As such, it would be surprising if dysregulation of O-
GlcNAcylation did not have an influence on sertoli cells, and subsequently the BTB. 
Additionally, “leaking” in the BTB is often associated with heat stress, which is implicated in 
many areas both male and female infertility (Hansen, 2009). As previously mentioned, O-
GlcNAcylation is upregulated during times of cellular stress or injury. Stress induced O-
GlcNAcylation promotes cell survival through regulation of: PI3K/Akt pathway, heat shock 
protein expression, calcium homeostasis, levels of reactive oxygen species, ER stress, protein 
stability, mitochondrial dynamics, and inflammation (Groves et al., 2013). Any of these 
mechanisms could have a significant influence on reproductive health. Heat stress is of particular 
concern in livestock species. Given this, understanding the role O-GlcNAcylation may play in 
the heat stress response could be crucial to agricultural species management, especially as we 
begin to face the realities of climate change (Sheikh et al., 2017).   
      Another environmental issue impacting reproduction is our pervasive exposure to 
environmental chemicals. Many of these chemicals have been shown to influence cell 
metabolism. Some notable examples include, Bisphenol A, PBDE (a category of flame 
retardants), some pesticides (DDT/DDE), and PFOA (Heindel et al., 2017), an industrial 
byproduct that has recently been discovered in the drinking water of many Vermonters. While 
these chemicals are already on the radar of many, there potential connection to disrupted O-
GlcNAc signaling have not been explored, and could be crucial in understanding the full impact 
these chemicals have on reproductive and metabolic health.  
        While this project presented me with many challenges and moments of frustration, this 
work has only fed my intrigue and excitement for glycobiology. I am grateful to have had the 
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experience of working in a new and excited field, and am especially aware of the unique and rich 
research opportunities that lay before me as I begin my career in academia. My appreciation for 
glycobiology has also become a component of my career goals as an educator. As an 
undergraduate I received minimal to no education in glycoscience, and I am shocked by the lack 
of glycobiology educational opportunities even at the graduate level. In 2012, the National 
Academies published a report at the request of the NIH, NSF, DOE, FDA, and the Howard 
Hughes Medical Institute, investigating the current state of the Glycosciences (Council, 2012). 
The report found that despite the obvious importance of glycobiology in all aspects of human 
and animal health, glycoscience is viewed as a niche research area, with limited funding or 
investment. While this is due to a variety of reasons stemming from the complex nature of the 
problem, the committee noted specifically, “a pervasive lack of knowledge by non-
glycoscientists, at all levels of education, about these types of molecules,” (Hart, 2012). I plan to 
approach my career as a researcher and an educator with at the fore front of my mind. I hope to 
share my enthusiasm for glycobiology with my students and colleagues in the classroom, 
laboratory and conference halls. 
      In conclusion, this body of work contributes significant interdisciplinary findings to the fields 
of reproduction, cancer biology, and glycobiology. It also provides clear scaffolding for future 
research in this and related areas of study. The process of compiling this work has illuminated 
my drastic evolution from an inexperienced graduate student to a productive, independent 
research scientist. I have acquired a diverse set of both technical and cognitive skills that have 
prepared me for a career as a scientist and educator, and I am grateful for further opportunities to 
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